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CHAPTER I. 
HEAD AND NECK SQUAMOUS CELL 
CARCINOMAS 
CHAPTER I. 
1. Incidence and therapy 
Squamous cell carcinomas are the most common malignant tumours of the head 
and neck. Head and neck cancer accounts for approximately 4% of all malignant 
neoplasms, with an estimated 42,900 new cases and 12,300 deaths in the United 
States of America in 1989 (1). In the Netherlands, the incidence rate according to 
the European standard population is 11.4, 1.6 and 0.9 per 100,000 population per 
year for the larynx, tongue and oropharynx in males and 0.6, 0.5 and 0.3 in 
females, respectively (2). Malignant neoplasms of the larynx account for 2.5% of all 
the tumours in males. The death rate in males is 3.0 and 3.1 per 100,000 population 
per year for laryngeal cancer and oral cancer, respectively (1,2). 
Good therapeutic results for head and neck cancer with limited extension can be 
obtained either by surgery or radiotherapy alone. For the early stage of laryngeal 
cancer (П) a 5 year actuarial survival rate of about 90% can be attained (3) and for 
carcinoma of the tongue up to 70%. The overall 5 year survival rate for all the 
stages together is about 40-50% for both laryngeal and tongue cancer (4). 
Despite many efforts to improve the treatment results by combining different 
treatment modalities, the figures have remained virtually the same over the past 15 
years. For some sites and stages it has been possible to reduce the local recurrence 
rate, however the overall survival rate has not increased because of an elevated 
rate of distant metastases and second primaries (5-7). 
Chemotherapy which is known to improve the survival rate for many types of 
cancer, such as testicular cancer, Hodgkin's disease, non-Hodgkin childhood 
lymphomas, acute lymphocytic leucemia and childhood sarcomas (8-13), has been 
used increasingly in patients with locally advanced head and neck cancer, espe­
cially in cases with recurrent and metastatic disease, which cannot be controlled by 
surgery and/or radiotherapy. 
The four most active and most frequently used agents for the treatment of head 
and neck squamous cell carcinomas are cisplatin, bleomycin, methotrexate and 5-
fluorouracil. The overall response rate of these agents used as single agent therapy 
varies from 15 to 80% (14-16). With a combination of drugs Vogl et al. (17) found 
an increase in the response rate from 35% for methotrexate alone to 48% for a com­
bination of methotrexate, bleomycin and cisplatin. An overall response rate of 70% 
has been reported for the combination of cisplatin and 5-fluorouracil in recurrent 
head and neck cancers (18) and 93% for previously untreated advanced squamous 
cell carcinomas of the head and neck (19). It has become clear that the tumour site 
and histopathology have a definite influence on the response rate, but that similari­
ties in tumour location and histopathology by no means assure that different 
patients will show similar responses to anticancer drugs. It would be a great step 
forward therefore to be able to predict a patient's individual response to chemothe­
rapy. 
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A general problem of cytotoxic drug treatment is the lack of reliable test systems 
which can predict the sensitivity of individual tumours to various drugs. 
The development of experimental models for studying the biological behaviour of 
malignant tumours and especially models for chemosensitivity testing have 
received a great deal of attention for a long time and both in vitro and in vivo 
short-term and long-term assays have been introduced. An important prerequisite 
for testing tumours outside the patient is the preservation of the biological proper-
ties of tumour cells in both in vivo and in vitro systems. 
2. In vivo models 
Researchers have been attempting to perform xenotransplantation of tumours for 
more than 50 years. By using immunologically privileged sites for heterotransplan-
tation such as the anterior chamber of the eye of rabbits and guinea pigs, it has 
became possible to grow h u m a n tumours in exper imenta l an imals (20). 
Unfortunately, the anterior chamber of the eye is small and therefore poses serious 
limitations. To overcome these problems, tumours have been transplanted intra-
cerebrally (21), but the main disadvantage of this method is that the grafts are not 
easily accessible for inspection. The hamster cheek pouch appears to offer a more 
appropriate site where tumour grafts can be inspected and followed fairly easily 
(22). To abrogate the possible influence of an immune response which eventually 
develops, irradiation and or cortisone treatment can be applied (23-25). 
In addition to these privileged sites, embryos and newborn animals have been 
used. In these animals, the immune system is still incompletely developed. 
However, the later aquired inununocompetence induces rejection of the grafts (26-
29). 
Apart from these animal models where graft rejection is mitigated or retarded, 
animal models where the immune system of the host is artificially suppressed have 
been introduced. Various methods have been applied to suppress the immune 
system: whole body radiation (30), whole body radiation plus cortisone (23), a 
combination of thymectomy, whole body radiation and bone marrow reconstitu-
tion (31), thymectomy and antilymphocyte serum (32) or thymectomy, cytosine 
arabinoside and whole body radiation (33). Although these models have produced 
satisfactory results the procedures are very time-consuming and long-term studies 
cannot be done because the induced immunosuppression is only temporary. 
An important breakthrough in the field of in vivo tumour models was the discove-
ry by Flanagan (34) of a nude mouse mutant with an autosomal mode of inheri-
tance, which was found to be athymic (35). The lack of a functional thymus-
dependent immune system allows the transplantation of human tumour cells into 
these animals without the risk of rejection. 
The first successful transplantation of a human colon carcinoma into these nude 
mice was performed by Rygaard and Povlsen in 1969 (36). Since then a growing 
number of reports have appeared on the behaviour of human malignant tumours 
xenografted into nude mice (37-39). Nearly all types of tumour have been xeno-
grafted with varying degrees of success. It has been established that the take rate 
largely depends on the tumour type and site. A remarkably low success rate has 
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been reported for the transplantation of some solid tumours also of squamous cell 
carcinomas of the head and neck region (40,41). 
The available data obtained from different tumours demonstrate that the biological 
and biochemical properties of the parent tumours are generally retained during 
serial passaging in nude mice (38,40,42-48). 
Tumour xenografts in the nude mouse can guarantee a continuous source of the 
same tumour tissue for studying cell characteristics and kinetics. Furthermore, this 
model offers the possibility of studying the effects of cytotoxic drugs in a syste-
matic way. 
Good correlations have been reported between the response of human tumour 
xenografts to cytotoxic drugs and the patients response for several human malig-
nancies (49-52). 
The suitability of this model for testing cytotoxic drugs on squamous cell carci-
nomas of the head and neck has been shown by Sneeuwloper and Lindenberger 
(53) and by Braakhuis et al. (41). However, the latter authors also reported that 
methotrexate, a most powerful drug against squamous cell carcinomas, gave only a 
minimal response in the nude mice, which did not correlate with the sensitivity of 
the source tumours (41). 
Although observations have shown that within certain limits the nude mouse is an 
attractive model for testing cytotoxic drugs, this model does not have any practical 
significance for predicting the chemosensitivity of individual patients. A major 
limitation is the duration of testing, which usually requires a period of about four 
months for fast growing tumours and more than one year for slow growing 
tumours. 
A more rapid in vivo method for cytotoxic drug testing, the subrenal capsule (SRC) 
assay, was introduced by Bogden et al. (54,55) in the late seventies. This method 
involves transplanting small pieces of solid tumours into the subrenal capsule of 
inununocompetent mice and then exposing them to various cytotoxic drugs. The 
difference between the volume of the treated and untreated tumours measured 
after 6 days is thought to be a reliable parameter for the effect of the drugs. The 
effect of a normal host versus graft reaction is assumed to be insignificant during 
this short period. 
The value of this assay is still a matter of debate. Aamdal et al. (56) and Rajnay et 
al. (57) found that the chemosensitivity profiles of xenografted human tumours 
using the 6-day subrenal capsule assay were of the same ranking as those of subcu-
taneous transplantation in nude mice. However, a detailed histological evaluation 
of over 800 SRC grafts revealed an intense inflammatory reaction and fibrosis and 
the complete absence or only a minor amount of tumour tissue in the majority of 
the grafts after 6 days (58). This indicates that the drug sensitivity patterns 
obtained with this assay using only macroscopic criteria do not correlate with the 
actual degree of tumour regression. 
The major drawback of the SRC assay therefore appears to be the difficulty in esta-
blishing whether the changes in the volume of the xenograft are due to changes in 
the number of tumour cells or to the inflammatory reaction. 
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3. In vitro models 
Apart from the in vivo models, several methods for in vitro chemosensitivity 
testing of human tumours have been introduced. So far none have found general 
acceptance. The oldest method is the cytologie-morphologie assessment of the 
action of cytotoxic agents in cell-tissue cultures. The first short-term cultures of 
human and animal tumours as a test system for cytotoxic agents were performed 
by Gellhom et al. (59) and Biesele (60). A better standardisation of the culture con-
ditions was reported by Eagle and Foley (61,62). Various modifications of the 
method of testing cytotoxic agents have since been developed by introducing the 
inhibition of dehydrogenase activity and the incorporation of radioactively labeled 
nucleic acid precursors as parameters for establishing drug effects (63-69). Despite 
the large number of investigations, it is not yet clear whether these tests allow any 
reliable conclusions on tumour behaviour. 
In 1977, Hamburger and Salmon (70) introduced an in vitro assay which measures 
the reproductive capability of tumour cells in soft agar. This stemcell assay has 
been widely advocated as a method for culturing human tumours and for prospec-
tively selecting the most appropiate anticancer drug for an individual patient. In 
retrospective and prospective clinical studies on ovarian cancer and multiple 
myeloma, Salmon et al. (71) reported true sensitivity and resistance predictions of 
92% and 100% respectively. In a review by Salmon the positive prediction rate 
varied from 60% to 92% and the negative prediction from 83% to 100% with an 
overall percentage of 71% and 91% (72). 
The main disadvantage of this method is that the proportion of human tumours 
which show clonal growth is frequently less than 50%. Von Hoff reported that 
from more than 8,000 tumours cultured only 31% had sufficient in vitro growth for 
drug testing and only 8% of the specimens with adequate growth demonstrated in 
vitro sensitivity to currently available antineoplastic drugs. This agrees with the 
data reported by Rozencweig et al. (74). They stated that only 34% of solid tumours 
were suitable for drug testing. 
Squamous cell carcinomas of the head and neck have also been tested using the 
clonogenic stemcell assay. However, because of the very low plating efficiency, 
Mattox et al. (75) concluded that the clonogenic assay does not contribute to the 
management of patients with cancer of the head and neck. 
Improvement of the plating efficiency of head and neck squamous cell carcinoma 
was obtained by passaging the tumours first in a thymic mice, but for some 
cytotoxic drugs there was no correlation between the in vitro and in vivo sensiti-
vity tests (76). 
A second disadvantage which can seriously interfere with the final results of this 
stemcell assay is the technique used for disaggregation of the tumours. Irrespective 
of the methods used, the tumour cell preparations invariably contain aggregates of 
tumour cells and such pre-existing cell aggregates are difficult to differentiate from 
proliferative cell colonies (77). In addition. Bijman et al. (78), in their study on head 
and neck squamous cell carcinomas, reported that each dispersal technique, either 
mechanical, enzymatic, chemical or a combined procedure, could yield typical cell 
suspensions which contained relatively different types and numbers of cells and 
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that this may influence the results of the in vitro drug sensitivity testing. 
Summarizing the difficulties associated with obtaining true single cell suspensions 
and the low plating efficiency for many tumour types, preclude the routine appli­
cation of h u m a n tumour colony forming assay for chemosensitivity testing 
(72,77,79-82). 
For in vitro chemosensitivity testing of tumour cell-lines several rapid colorometric 
assays have been described. In recent years, the tetrazolium ( M i l ) assay, has been 
the most widely used method (83, 84). This method is based on the ability of living 
tumour cells to reduce a tetrazolium-based component (3-(4/5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) to a blue formazan product. However, the 
MTT assay for drug sensitivity testing of primary tumour samples is limited 
because the contaminating normal cells may also reduce the tetrazolium. Therefore 
it only offers a valid and simple method of assessing chemosensitivity in esta­
blished cell lines (83). The sulforhodamine В protein stain (SRB) assay for in vitro 
chemosensitivity testing provides a better linearity with cell number and a higher 
sensitivity than the MTT assay. In contrast to the MTT assay, the SRB assay stains 
recently lysed cells and the cell debris is not stained, as was reported by Skehan et 
al. (85) and Keepers et al. (86). 
4. Purpose of this study 
In view of the difficulties encountered with the in vitro models, the use of nude 
mice as an in vivo model for growing and testing human tumours may have more 
clinical relevance than culturing disaggregated single tumour cells in an artificial 
environment. 
In this study, some characteristics of the nude mouse as a model for studying 
human head and neck squamous cell carcinomas are further explored. 
Chapter II deals with the take rate and growth characteristics of human squamous 
cell carcinomas. In chapter III the stability of the DNA content of these tumours 
was studied during serial passaging with the use of DNA cytometry. In chapter IV 
the value of this model for testing cytotoxic drugs is analysed using growth curves, 
histology and the DNA profile as parameters. In chapter V a method is introduced 
for the production and incubation of thin tumour slices of equal thickness for 
cytotoxic drug testing. In chapter VI the reliability of two different in vitro chemo­
sensitivity tests, is investigated. 
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CHAPTER П. 
GROWTH CHARACTERISTICS OF 
HEAD AND NECK SQUAMOUS CELL 
CARCINOMAS IN NUDE MICE 
Part of this chapter has been published in: Eur J Cancer Clin Oncol 22:1211-1222, 
1986 by: Elprana D, Kuijpers W, van den Broek Ρ and Wagener DJTh. 
1. Abstract 
Growth behaviour of human squamous cell carcinomas from the head and neck 
region was studied in nude mice. Tumour growth was observed in 10 out of 13 
tumours transplanted, including 2 lymph node metastases. The take rate percen-
tage related to the number of tumour inocula used, varied from 10 to 90% in the 
first passage and from 70 to 100% in the subsequent passages. No significant diffe-
rence could be established in the growth pattern, except from the first to the 
second passage. Histological studies demonstrated preservation of the original 
histopathological features, invasion of two tumour lines into the fibrous capsule, 
but no distant metastasis. Comparison of growth curves with histological features 
demonstrated that growth curves are not a reliable measure for the number of 
vital tumour cells present. 
The time needed for the tumour to obtain a diameter of about 4 mm proved to be a 
reliable parameter for the determination of the growth characteristics. It is 
concluded that both growth curves and histology are indispensable when growth 
behaviour of xenografted tumours is studied. 
2. Introduction 
Since the first successful transplantation of a human colon carcinoma in athymic 
nude mice (1), many studies dealing with xenotransplantation of a large variety of 
malignant tumours in this animal model have been reported (2-4). 
These tumours present during repeated passages in this animal a histopathological 
picture, which appears very similar to that of the original tumour (3,5,6), although 
the degree of differentiation may show some variation (3,4,6,7). In addition, the 
human origin of the growing tumour cells has repeatedly been demonstrated by 
chromosome analysis (8). The degree of success in establishing a tumour line 
varies considerably between various tumour types and appears to be largely 
dependent on the degree of cellular differentiation and whether tumours are used 
from the primary site, from metastases or from recurrent tumours (2,4,5,9-12). 
Only limited data are available on the transplantability and growth behaviour of 
squamous cell carcinomas of the head and neck region in the nude mouse (10,13-
18). These studies reveal a low take rate, varying between 26 and 40% for primary 
transplants and of about 50% for subsequent passaging. Although the factors 
responsible for this invariably low take rate are not fully understood, it has been 
discussed that the degree of differentiation (10,15) and the possibility of bacterial 
contamination of the primary grafts (10) play an important role. 
However, Wennerberg et al. (15) failed to find a significant difference in take rate 
between specimens taken as non-sterile biopsies and as sterile excisions. Growth 
characteristics of these tumour xenografts have only been determined from meas-
urements of tumours grafted subcutaneously and hardly any data are available 
which compare growth curves and histological features. 
This report deals with transplantation of a series of head and neck squamous cell 
carcinomas into nude mice with special reference to primary take rate, serial 
passaging and histology as well as to the interrelationship between histological 
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features and growth curves. 
3. Materials and Methods 
3.1. Transplantation 
Tumour tissue was obtained from fresh surgical specimens of 11 previously 
untreated squamous cell carcinomas from different primary sites in the head and 
neck region and 2 lymph node metastases. A solid piece of tumour measuring 
about 1 cm3 was dissected from the surgical specimen, under sterile conditions, 
immediately after removal from the patient. Since the surface of the tumour is 
always contaminated, the specimens were dissected from the deeper parts of the 
tumour and the necrotic tissue was removed. Further cleansing was achieved by 
rinsing the tumour tissue three times in cold balanced Hank's solution (40C). The 
tissue was subsequently stored in this solution until use. 
Transplantation was performed within 1 hr of tumour excision. For inoculation of 
the tumour into the nude mouse, the tissue block was cut into pieces of about 1-2 
mm
3
 and these were implanted subcutaneously in the flank of the n u d e mice 
(female Balb/c, n u / n u , age 7-12 weeks, obtained from TNO-breeding unit, 
Rijswijk, The Netherlands). The mice were kept in cages with filter caps and 
provided with sterile bedding, food and drinking water containing Terramycin 
(250 mg/1). The ambient room temperature was 260C and the air humidity 70%. 
For serial transplantation, the tumour graft was removed under ether anaesthesia 
and the same procedure was followed as for the primary transplants. The number 
of mice used for each tumour varied between 10 and 20. 
Tumour growth was measured with the use of a Vernier caliper at weekly inter­
vals, and biweekly in the case of rapidly growing tumours. Tumour volume was 
calculated as 0.5 χ the product of the three dimensions and was plotted on a linear 
scale (19). 
3. 2. Microscopy 
After varying survival times, the mice were sacrificed with ether and the entire 
tumours dissected. The animals were inspected for the presence of metastases. For 
light microscopy, fragments from the original tumours, the entire xenografts and 
the draining lymph nodes were fixed in phosphate buffered (0.1M; pH 7.4) formal-
dehyde(4%)/ dehydrated in graded alcohols and embedded in paraffin or glycol 
methacrylate. Sections (3-7 μιή) were stained either with haematoxylin-eosin, 
toluidin blue, methylgreen pyronin or Masson-Goldner for keratin. 
For electronmicroscopy, small tumour fragments were fixed in phosphate buffered 
(0.1M; pH 7.4) glutaraldehyde (2%) for at least 4 hours. After postfixation in 1% 
osmium tetroxide in phosphate buffer (0.1M; pH 7.4) for one hour, the specimens 
were rinsed in buffer and after dehydration in graded alcohols embedded in Epon 
(20). Ultrathin sections were contrasted with saturated aqueous solution of uranyl 
acetate (21) and subsequently with lead citrate (22). The sections were examined 
with a Philips EM 300 electronmicroscope. 
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4. Results 
4 .1. Take rate 
A total number of 11 primary squamous cell carcinomas and two lymph node 
metastases were transplanted. The sites of origin, the TNM- and the histopatholo-
gical classification are shown in Table 2.1. Growth of the primary tumour was 
achieved in 9 out of 11 cases corresponding to 82%. From the two transplanted 
lymph node metastases only one appeared to grow. Tumour lines were subse-
quently established from all the growing tumours (100%). The passage levels are 
indicated in Table 2.1. The take rates, i.e. the proportion of tumour grafts of a 
single tumour resulting in growth in the first and subsequent passages, are sum-
marized in Table 2.II. These data show a low primary take rate of the inocula for 
seven out of 12 tumours. This take rate increased considerably sometimes to 100% 
in subsequent passages. 
4. 2. Growth curves 
Growth curves of transplants from a single tumour revealed a large variation. This 
was true not only for the primary transplants, but also for the subsequent passages 
as shown in Fig. 2.1 for tumour HN-5. The variation in the growth curves could 
not be related to the size of the inoculum, since it appeared that transplantation of 
tumour fragments of different size failed to show any clear correlation between 
the size and type of growth curve. 
In order to study the possiblity as to whether selection of fast and slow growing 
populat ion of tumour cells might be the underlying cause of the observed 
variation of the growth curves, fragments of tumours with a slow and an accela-
rated growth pattern were transplanted. Both resulted in a comparable variation 
of the growth curves. Because of this large individual variation of growth curves 
obtained from one tumour, these curves could not be used as a reliable parameter 
for calculating the growth rate in the various passages. The duration of the initial 
lag-phase, i.e. the time needed for the tumour to obtain a general mean diameter of 
about 4 mm, was therefore chosen as the parameter for growth. 
The initial lag-phase appeared to be the largest for the first passage and to de-
crease in the higher passages to a rather stable value, as determined for six 
tumours (Table 2.III). The initial lag-phase for the first passage appeared to vary 
between 3.6 and 9.8 weeks, with the exception of tumour HN-7 which showed the 
extra-ordinarily high value of 33 weeks. In further passages, the initial lag-phase 
varied between 1.1 and 5.1 weeks. No significant difference was found for this 
value between the primary tumour HN-2 and its lymph node metastasis HN-2M. 
4. 3. Light- and electronmicroscopy 
Histological examination of the transplanted tumours demonstrated preservation 
of the original histopathological characteristics in all passages studied (Figs. 2.2, 
2.3 and 2.4). Only tumour HN-7 showed a slight dedifferentiation. Metastasis to 
lymph nodes or other organs was not observed in any of these lines. Throughout 
the observation period all tumours were surrounded by a fibrous capsule contai-
ning many capillaries. Because of the limited number of tumours available from 
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Table 2.1. Head and neck squamous cell carcinomas transplanted into nude mice. 
Localization 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10 
11 
12. 
13. 
Supraglottic (HN-1) 
Epiglottic (HN-2) 
Lymph node met.(HN-2M)*' 
Epiglottic (HN-3) 
Piriform sinus (HN-4) 
Tongue (HN-5) 
Tongue (HN-6) 
Epiglottic (HN-7) 
Tongue (HN-8) 
Supraglottic (HN-9) 
Piriform sinus 
- Lymph node met.(HN-lO) 
Tongue (HN-11) 
Tongue (HN-12) 
Stage 
T1N2M0 
T2N1M0 
> T2N1M0 
T4N1M0 
T2N1M0 
T2N0M0 
T2N0M0 
T1N0M0 
T1N0M0 
T3N0M0 
T1N1M0 
T2N1M0 
T2N0M0 
Histology 
Poorly diff., 
keratinizing 
Mod. diff. 
keratinizing 
Mod. diff., 
keratinizing 
Poorly to mod. diff., 
keratinizing 
Mod. diff., 
keratinizing 
Mod. diff., 
keratinizing 
Mod. to well diff., 
keratinizing 
Well to mod. diff., 
focallykeratinizing 
Mod. diff., 
non keratinizing 
Mod. to well diff., 
keratinizing 
Mod. to well diff., 
keratinizing 
Mod. diff., 
keratinizing 
Poorly to mod. diff., 
non keratinizing 
Passage 
No growth 
10th 
10th 
No growth 
10th 
5th 
6th 
3rd 
3rd* 
4th 
No growth 
3rd* 
2nd* 
Overall primary take rate 10/13 (77%). Take rate primary tumours 9/11 (82%). 
* Terminated at indicated passage. ** Lymph node metastasis of HN-2. 
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Table 2.II. Percentual take rate (number of takes in relation to the number of mice transplantated). For the first passage 10 
mice were used. For serial passaging the number of mice varied between 10 and 20. 
Tumour 
1. HN-1 
Ζ HN-2 
3. HN-2M 
4. HN-3 
5. HN-4 
6. HN-5 
7. HN-6 
8. HN-7 
9. HN-8 
10. HN-9 
11. HN-10 
1Z HN-11 
13. HN-12 
1st 
0(0/10) 
30(3/10) 
* 10(1/10) 
0(0/10) 
10(1/10) 
100(10/10) 
30(3/10) 
10(1/10) 
20(2/10) 
20(2/10) 
0(0/10) 
90(9/10) 
80(8/10) 
2nd 
80(8/10) 
30(3/10) 
80(8/10) 
Passages 
3rd 4th 5th 
100(10/10) 100(20/20) 85(17/20) 
86(12/14) 100(18/18) 100(20/20) 
92(12/13) 93(14/15) 80(16/20) 
100(15/15) 93(14/15) 100(8/8) 100(8/8) 
100(10/10) 87(13/15) 100(20/20) 80(16/20) 
90(9/10) 
90(9/10) 
20(2/10) 
60(6/10) 
90(9/10) 
100(10/10) 
90(9/10) 
100(10/10) 100(10/10) 
80(8/10) 
6th 
85(17/20) 
90(18/20) 
80(12/15) 
80(12/15) 
7th 8th 9th 10th 
100(20/20) 100(20/20) 100(20/20) 100(20/20) 
100(17/17) 100(10/10) 100(10/10) 90(18/20) 
85(17/20) 70(14/20) 100(10/10) 75(15/20) 
* Lymph node metastasis of HN-2. 
0 4 8 , 0 4 β 
— weeks — weeks 
Figure 2.1. Growth curves of tumour 5 (HN-5) during the first four passages. Growth 
curves of tumours which were used for histological studies, during the first 5 weeks are not 
indicated. 
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Table 2.Ш. Initial lag phase of six established head and neck squamous cell carcinoma lines. Initial lag phase (in weeks ±S.D.; 
n: number of tumours measured) is defined as the time needed to obtain a general mean diameter of about 4 mm. 
Tumour 
l.HN-2 
2HN-2M* 
3.HN-4 
4.HN-5 
5.HN-6 
6.HN-7 
1st 
7.0 ±0.50 
n=3) 
7.4 
(n-1) 
9.8 
(n-1) 
3.6 ± 0.01 
(n-10) 
9.10 ±0.02 
(n-3) 
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(n-1) 
2nd 
4.30 ± 0.80 
(n-8) 
1.19 ± 0.06 
(n-14) 
1.08 ±0.30 
(n-10) 
3.13 ± 0.38 
(n-9) 
3rd 
3.48 ± 0.63 
(n=10) 
5.10 ± 0.20 
(n=12) 
3.65 ± 200 
(n=12) 
1.80 ±0.08 
(n=14) 
2.68 ±0.71 
(n-13) 
3.76 ± 1.85 
(n-10) 
4th 
3.52 ±1.67 
(n=20) 
4.53 ± 1.63 
(n=18) 
2.46 ± 0.70 
(n=10) 
210 ±0.10 
(n=8) 
3.81 ±1.28 
(n=20) 
Passages 
5th 
3.17 ±1.24 
(n=17) 
3.45 ± 1.57 
(n-20) 
267 ±1.16 
(n=14) 
1.97 ±0.18 
(n=8) 
3.70 ±1.05 
(n-16) 
6th 
3.24 ± 2.15 
(n-17) 
4.35 ± 1.70 
(n=19) 
205 ±0.04 
(n=10) 
290 ±0.98 
(n-12) 
7th 
2.60 ± 0.08 
(n-20) 
3.01 ± 1.11 
(n=17) 
1.55 ± 0.81 
(n=17) 
8th 
3.02 ±1.20 
(n-20) 
4.05 ± 254 
(n-10) 
1.36 ± 0.35 
(n=14) 
9th 
286 ±0.53 
(n-20) 
3.80 ± 0.01 
(n-10) 
206 ±1.01 
(n-10) 
10th 
3.77 ±1.74) 
(n-20) 
3.20 ± 0.92 
(n-18) 
247 ± 0.% 
(n-15) 
* Lymph node metastasis of HN-2 
the primary passages, histology of tumour growth was mainly studied in the sub-
sequent passages. 
After 1 week, the implantation site showed scattered islands of proliferating 
tumour cells concentrated in the periphery of the tumour transplant and accumu-
lations of extravasated erythrocytes, fibroblasts and capillaries (Fig.2.3 ). This area 
was separated from the surrounding host tissue by a layer of fibroblasts with 
numerous granulocytes and capillaries. After 2 weeks, the islands of tumour cells 
had grown together ( tumour size about 2 mm3), forming one tumour mass 
(Fig.2.4A). Subsequently, the tumour developed a distinct compartimentalization. 
The various compartments were separated by connective tissue septa containing 
capillaries (Fig.2.4 B,C.). These septa were lined by a basal layer of regularly 
arranged tumour cells containing numerous mitotic figures (Fig.2.4 C) These were 
also observed in the periphery of the tumour bordering the fibrous capsule. 
Electronmicroscopy of the xenografts showed a tumour mass surrounded by a 
desmoplastic connective tissue. The tumour was separated from the stroma by a 
basal lamina of a varying architecture, locally showing thickening, multilayering 
as well as discontinuities. The tumour cells revealed a largely varying number of 
desmosomes, however at some sites these intercellular connections were comple-
tely absent. The same was found for hemidesmosomes forming the connection 
between the tumour cells and the basal lamina (Figs.2.5; 2.6). Occasionally, 
processes of the tumour cells were found to penetrate through the basal lamina 
into the surrounding stroma (Fig.2.6 A,B). These phenomena were found in the 
different passages as well as in the primary tumours. 
During further growth of the tumour, necrosis and/ or desquamation became the 
most conspicious finding in the central parts of the tumour. This was often already 
marked at a tumour size of 30-50 mm3 (Figs.2.7A; 2.8A,C). The presence of cellular 
debris, dyskeratosis and/or keratinization appeared to differ from line to line and 
was related to the degree of keratinization and the size of the tumours (Figs.2.7; 
2.8). In all xenografts larger than 100 mm3, the major part of the tumours consisted 
of debris, dyskeratosis a n d / o r keratin lamellae (Figs.2.8B; 2.9A), sometimes 
showing a typical onion skin appearance (Fig.2.8B). In these larger tumours, the 
presence of tumour cells was limited to the peripheral part and the connective 
tissue septa, which often showed progressive degeneration (Figs.2.7C; 2.8D; 2.9). 
Throughout the observation periods, invasion of tumour cells into the fibrous 
tissue was found in two tumour lines (HN-2 and HN-4) (Fig.2.10). This gave rise to 
the formation of satellite tumours, contributing to a lobular appearance. The 
earliest capsular invasion was already demonstrable after two weeks at a tumour 
size of 2 mm'. 
At a tumour size of more than 300 mm3, an increasing number of tumours fluctu-
ated on palpation and appeared to be filled with a viscous fluid (Fig.2.11). This 
was especially marked in the non-keratinizing tumours and those showing dyske-
ratosis. 
Apart from differences in degree, this course of events was noticed in all tumour 
lines studied during various passages. Tumours which from their growth curves 
were classified as slow growing, revealed the same histological features as fast 
growing tumours after comparable survival times. 
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Figure 2.3. Micrographs of primary tumour HN-4 (A) and its growth characteristics in 
the nude mouse, after 1 week (4* passage; B: survey; C: detail) The site of implantation is 
surrounded by a fibrous capsule containing numerous inflammatory cells. Clusters of 
growing tumour cells are present in the peripheral part. Trie central part contains extra-
vasal erythrocytes and fibrocytes (Haematoxylin-eosin, A,C: χ 185; Β: χ 40). 
*- Figure 2.2. Micrographs of primary tumours (left) and their xenografts (right), showing 
preservation of the original histopathological characteristics: A: primary tumour HN-6; B: 
4" passage. C: primary tumour HN-5; D: З"1 passage. (Haematoxylin-eosin; χ 185). 
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Figure 2.4. Micrographs of tumour HN-4 (4* passage), 2 (A; tumour size 2,0 mm3) and 3 
weeks (B, C; tumour size 12.0 mm3) after xenografting. Fig. A shows encapsulated tumour 
mass with connective tissue septa of varying size in between. Fig. В shows one massive 
tumour, composed of various compartments. First signs of central necrosis are clearly 
visible at higher magnification in С (χ 185) (Toluidin blue) 
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Figure 2.5. Electronmicrographs of xenografted tumour HN-2 showing local variation in 
the distribution of desmosomes and hemidesmosomes. Note multilayering (ml) of the basal 
lamina in A. c: fibrous capsule. (A: χ 8,000; Β: χ 9,000). 
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Figure 2.6. Electronmicrographs of xenografted tumours HN-2 (A) and HN-4 (B,C) 
showing microinvasion (m) of the tumour cells into the fibrous capsule (c). Note the 
complete absence of desmosomes and hemidesmosomes in А, В and C. (arrow: disruption of 
thickened basal lamina; (ml): multilayering of basal lamina; A: χ 15,000; Β: χ 5,400; С: χ 
9,000). 
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Figure 2.7. Micrographs of tumour HN-4 (5th passage), 4 (A; tumour size 40 mm') and 5 
weeks (B, C; tumour size 80 mm3) after transplantation, showing progressive central 
necrosis. By jar the largest part of the tumour in В consists of dead material. Higher magni­
fication (x 185) in С shows central degeneration of tumour and connective tissue septa. 
(Haematoxylin-eosin). 
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Figure 2.8. Micrographs of tumour HN-2 (8th passage) after 4 lüeefcs (A, C; tumour size 50 
mm
3) and tumour HN-6 (2nd passage) after 6 weeks (B, D; tumour size 200 mm3). Note 
starting keratinization in the central parts of tumour HN-2 and the onionpeel appearance 
of the strongly keratinizing tumour HN-6. This tumour consists of a large mass of keratin, 
surrounded by a thin layer of vital tumour cells. (A, C: Masson-Goldner; B, D: 
Haematoxylin-eosin; C: χ 90; D: χ 185). 
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Figure 2.9. A. Micrograph of tumour HN-4 (4Й passage) after 6 weeks (tumour size 300 
mm
3). Vital tumour cells are only present in the periphery and along the vascularized con­
nective tissue septa. B. Higher magnification of septum with vital tumour cells and central 
capillary (Haematoxylin-eosin; Β: χ 185). 
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Figure 2.10. Survey and detail of invasion of tumour cells of tumour HN-4 into the fibrous 
capsule, 2 weeks after transplantation (a* passage). (Toluidtn blue; A: χ 125; Β: χ 400). 
Figure 2.11. Micrograph of tumour HN-2 (6Λ passage; tumour size 500 mm3) showing 
cystic structure with central liquification. (Haematoxylin-eosin). 
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5. Discussion 
The present study demonstrates that tumour lines of squamous cell carcinomas 
from the head and neck region can be established in nude athymic mice, generally 
retaining the original histopathological features of the donor tumours. No meta-
stases to lymph nodes or other organs were observed. These observations 
generally agree with those made by other authors (10, 15,16), although both 
increased and decreased cellular differentiation have been described by Sharkey et 
al. (4,7) and Braakhuis et al. (10). Kyriasis et al. reported a lymph node metastasis 
of a human epidermoid carcinoma of the larynx in nude mice (23,24). 
The transplants grew as circumscribed and encapsulated tumours without infiltra-
tion into the surrounding tissue, except for the invasion into the fibrous capsule. A 
comparable observation has been made in a human laryngeal epidermoid carci-
noma by Kyriasis et al. (23). 
In comparison with other studies on transplantation of squamous cell carcinomas 
of the head and neck region in nude mice, a high take rate of primary grafts and 
subsequent passages has been obtained in this study. This difference is difficult to 
explain, but the high take rate in this study (an overall take rate of 77% and 82% of 
primary tumours) demonstrates that head and neck carcinomas can be trans-
planted more successfully than has been described in previous experiments 
(10,15). It indicates that they do not belong to the category of solid tumours which 
are difficult to transplant successfully like gastric, mammary and genital tract 
tumours. 
Because the suggestion has been made that poorly differentiated tumours have a 
better primary take rate than moderately and well differentiated head and neck 
squamous cell carcinomas (10,15), the degree of differentiation of the transplanted 
tumours might be held responsible for this difference in take rate. However, the 
present findings give no support to this, although the number of tested tumours is 
small. In this study a primary take rate of 82% was obtained chiefly with mo-
derately to well differentiated tumours, while two out of the three tumours, which 
failed to take were poorly to moderately differentiated. 
Also tumour site (10,15,25) tumour size, (15,25) malignancy grading (25) and the 
clinical course (26,27) have been suggested to influence tumour growth in nude 
mice. According to Wermerberg et al. (25) tumour size should be more important 
than the degree of differentiation. However, the small number of tumours of 
various categories tested in the present study and the absence of data on the 
clinical course do not permit to conclude on the existence of such a correlation. 
A more acceptable explanation for the difference in take rate between the present 
study and those of others is likely to be found in the implantation technique, the 
number of inocula t ransplanted and the prolonged period of observation. 
Comparable suggestions have been made by Somers et al. (28). The data given in 
Table 2.II indicate that the number of primary takes with respect to the number of 
inocula used is often very low (sometimes only 1 out of 10). In the further passages 
the take rate increases considerably, sometimes reaching 100%. This is a confirma-
tion of previous studies (10,29). A recent attempt to enhance the primary take rate 
of human squamous cell carcinoma of the head and neck in nude mice by total 
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body irradiation of the host failed to improve the take rate (30). 
Determination of the growth rate of squamous cell carcinoma xenografts appeared 
to be difficult, owing to the large divergency between growth curves of the same 
tumour. This variation could not be attributed to the presence of fast and slow 
growing populations of tumour cells or to the size of the inocula, because initially 
the nutrition of the transplanted tumour is merely dependent on diffusion and 
therefore only the cells in the peripheral part will survive (Fig.2.3.B,C) (31). With a 
larger inoculum only the initial lag-phase will change. 
Although host factors relating to the mitigated immune response and to the 
vascular supply of the tumours cannot be entirely excluded as possible explana-
tions for the variation in growth curves, the histological observations suggest that 
accumulation of cellular debris and keratin lamellae within the tumour is a major 
contributing factor. This study also demonstrates that increase in the size of 
tumours beyond 50 mm3 is influenced by cellular debris and desquamation 
products. This influence increases with the size of the tumour and shows indivi-
dual variation. Calculation of growth rate of larger squamous cell carcinoma xeno-
grafts, from tumour doubling time is therefore an unreliable measure, because it is 
not related to the fraction of vital tumour cells, but chiefly to the amount of accu-
mulated dead material. In view of these observations, the time needed for the 
tumour to obtain a general mean diameter of about 4 mm (initial lag-phase) 
proved to be a more reliable parameter in determining tumour growth characteri-
stics. During this period the contribution of dead material to the size of the tumour 
is negligible. 
This approach revealed a rather long initial lag-phase for primary transplants, 
decreasing in the subsequent passages to a limiting maximum value, and varying 
between different tumour lines. A comparable difference between the growth rate 
of the primary transplant and subsequent transplants has also been established by 
other authors for various other human tumour lines (8,11,32). 
These data together with the difference in the take rate for primary transplants 
and following transplants, are suggestive of an adaptation of the tumour to the 
changed environmental conditions in the host which is assumed to result in an 
increase in the growth fraction as well as a reduction in the cell loss factor in sub-
sequent passages (33-35). 
The decrease in passage time observed between first and subsequent passages cor-
responds with an increased mitotic activity from first to second passage reported 
by Fu and Steel for rat mammary tumours (35) and with the increase in S^phase 
percentage cells in human lung tumours (36). An increased rate of 3H-thymidine 
incorporation in tumour DNA during the second passage when compared with 
the first passage of head and neck squamous cell carcinomas, was reported by 
Wennerberg et al. (15). They suggested that this might be explained by a recruit-
ment of G0 cells or by stem cell selection of clones of rapidly proliferating cells. 
This latter suggestion however seems to be in conflict with the observation of 
Lindenberger (37) who, using cytofluorometry, failed to find any change in DNA 
profiles in xenografts of squamous cell carcinomas from first to third passage. 
Summarizing, this study demonstrates that squamous cell carcinomas from the 
head and neck region can be successfully established as lines in athymic nude 
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mice with preservation of their original histopathological features. Combined 
studies of both growth curves and histology are indispensable when investigating 
growth rate and growth behaviour, owing to the absence of a distinct relationship 
between tumour size and the amount of vital tumour tissue. This is of special 
importance when this model is used for evaluating the effect of various therapies. 
4Я 
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CHAPTER III. 
DNA-CYTOMETRIC STUDIES ON XENOGRAFTS OF 
SQUAMOUS CELL CARCINOMAS OF THE HEAD AND NECK 
This chapter has been published in: 
Anticancer Res 11: 1943-1950,1991 by Elprana.D, Kuijpers W, Peperkamp AR and 
Wagener DJTh. 
1. Abstract 
The primary tumours of four human head and neck carcinomas and their xeno-
grafts in nude mice were analysed with respect to their histological features and 
DNA ploidy level using DNA flow and DNA image cytometry. It was established 
that the histological characteristics and the DNA index of the xenografts did not 
differ from those of the parent tumours, whereas the growth rate remained stable 
during serial passaging. DNA flow cytometric analysis revealed the presence of 
both aneuploid and euploid cells in both parent tumours and their xenografts. 
During passaging the proportion of aneuploid cells increased. Analysis of the 
different cell populations by DNA image cytometry revealed the presence of 
aneuploid tumour cells and euploid host cells. This study demonstrates that the 
characteristics of the original tumours in terms of histological features and DNA 
ploidy are retained after xenografting. 
2. Introduction 
The biological and clinical relevance of in vivo studies on xenografted tumours 
largely depends on the preservation of the characteristics of the original tumours in 
the animal model. 
Since the first successful transplantation of a human cancer in athymic nude mice 
by Rygaard and Povlsen (1) several characteristics have been studied on a large 
variety of tumour xenografts. From these studies it has become clear that, except 
for slight changes in the degree of histologic differentiation in some cases, the 
original histologic features of the human tumours including head and neck 
squamous cell carcinomas are retained during serial passaging in nude mice (2-10). 
The same holds true for the preservation of the human chromosome constitution 
(6,11), the hormonal function (12-14) and other biochemical characteristics (15). 
With respect to the cell kinetic characteristics of the xenografts, it has been esta-
blished that the growth rate is generally stable over a considerable number of 
passages (10,16, 17). An increase in the growth rate during the first passages 
reported by some authors, has been attributed to an increased growth fraction and 
a reduced cell loss factor (18-21). 
Also the cell cycle parameters are found to resemble closely these of the original 
tumour (22). 
Although studies on the maintenance of the DNA ploidy status after xenografting 
are rather scarce, the available data from various tumours show that the DNA 
content generally remains stable during passaging in the nude mouse (23-25). 
However the stability of this parameter has hardly been investigated in head and 
neck squamous cell carcinomas and the obtained results are controversial with 
respect to the preservation of the original clonal composition (7, 21). 
As the cellular DNA content seems to be related to therapy responsiveness and 
prognosis (26-30), the preservation of this parameter is of crucial importance for 
making xenografted tumours a reliable model for drug sensitivity testing. 
The purpose of the present study was to determine whether xenogeneic head and 
neck squamous cell carcinomas retain the DNA ploidy and histological features of 
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the original tumours after xenografting during serial passaging in nude mice. 
3. Materials and Methods 
Tumour tissue was obtained from fresh surgical specimens of previously untreated 
primary squamous cell carcinomas of the head and neck region and processed 
aseptically both for transplantation in nude mice and for measuring the DNA 
content by flow cytometry according to previously described methods (10, 31). 
Their site of origin and further characteristics are summarized in Table 3.1. 
3.1. Transplantation 
For xenografting a piece of vital tumour tissue measuring about 1 cm3 was dissec­
ted under sterile conditions from the deeper parts of the surgical specimen, imme­
diately elfter removal from the patient. Subsequently the tumour tissue was rinsed 
thoroughly in cold (40C) balanced Hank's solution. Transplantation was performed 
within 1 hour after tumour excision. For that purpose the tumour tissue was 
minced into pieces of about 1-2 mm 3 and 6-10 pieces were implanted subcutane-
ously over the flanks of 3-5 female Balb/c, n u / n u mice, age 8-10 weeks under ether 
anesthesia as described previously (10). 
The remaining tumour fragments were used for flow cytometry and histological 
studies. 
The mice were kept in cages with filter caps and provided with sterile bedding, 
food and drinking water. The ambient temperature was 260C and the air humidity 
70%. Tumour lines were maintained by retransplantation of regrown tumour xeno­
grafts in 3-5 mice in the same manner as with the primary tumours. 
3. 2. Histology 
For comparison of the histological features of the original tumours with those of 
the xenografts and for DNA image cytometry, the tumour tissue was fixed in 
phosphate buffered (0.1M) formaldehyde (4%, p H 7.4). After dehydration in 
graded alcohols the specimens were embedded in paraffin. For histological studies 
sections (7 μιη) were stained with haematoxylin-eosin. 
3. 3. Immunohistochemistry 
For establishing the nature of the stroma in the xenografts a monoclonal antibody 
MECA-20 (kindly provided by Dr. A.M. Duijvestijn, University of Limburg, The 
Netherlands) directed against mouse endothelium was used (32). 
For immunohistochemical staining tumour xenografts were frozen in liquid N 2 
immediately after dissection from the mouse. Cryostat sections (7 μιη) were placed 
on poly-1-lysine coated slides and dried at room temperature. 
The sections were shortly fixed in cold aceton, rinsed in phosphate buffered saline 
(PBS, pH 7.4) and incubated with the monoclonal antibody MECA-20 (diluted 1:20 
in PBS) for 60 minutes at room temperature. After rinsing in PBS, the sections were 
incubated with peroxidase conjugated rabbit anti-rat serum (diluted 1:50 in PBS) 
containing 20% normal mouse serum for 30 min., again r insed in PBS and 
incubated with peroxidase conjugated swine anti-rabbit serum (diluted 1:50 in 
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Table 3.1. Squamous cell carcinomas of the head and neck region: tumour characteristics and patients survival. 
Localization 
A. Floor of the mouth 
(HN-13) 
B. Epiglottis 
(HN-14) 
C. Trigonum retromolare 
(HN-15) 
D. Floor of the mouth 
(HN-16) 
Stage 
T2N0M0 
T1N1M0 
T2N1M0 
T2N0M0 
Histology 
Mod. to well diff., 
keratinizing 
Mod. to well diff., 
keratinizing 
Mod. to well diff., 
keratinizing 
Mod. diff., 
keratinizing 
DNA index 
2.0 
1.8 
2.2 
1.65 
(DI) Survival (months) 
alive; 41 
alive; 41 
died of 
relapse; 15 
alive; 24 
PBS) as a second antibody containing 20% normal mouse serum. Following rinsing 
in PBS, peroxidase activity was detected by incubation in 0.05 M Tris-HCl buffer 
(pH 7.8) containing 1% 3,3 diaminobenzidin tetrachloride and 0.01% H 2 0 2 . The 
sections were rinsed in tap water, counterstained with Mayer's hemalum and 
embedded in DPX. 
3. 4. DNA flow cytometry 
For DNA flow cytometry the fragments obtained from the primary tumours and 
xenografts were washed twice in Hank's balanced salt solution and once in Eagle's 
minimal essential medium (MEM). After preincubation in MEM, containing colla-
genase (2 mg/ml, type II, 132 U/mg, Cooper Biomedical) and hyaluronidase (0.5 
mg/ml, type I, 370 U/mg, Sigma), for 1 hour at 370C under mild agitation, the 
tissue suspension was allowed to settle in the test-tube for 5 minutes and the 
supernatant containing mainly lymphocytes was subsequently discarded. 
The residual tumour tissue was incubated with trypsin (0.25 mg/ml) and dithio-
erythritol (3 mg/ml) overnight at 40C in Hank's balanced salt solution. 
After centrifugation at 200 g, the pellet was resuspended in 4 ml MEM supple­
mented with 10% heat-inactivated fetal bovine serum (FBS, Gibco Europe) and 100 
μΐ RNase (2.5 mg/ml) and incubated for 30 minutes at 37CC under agitation. 
Any undissociated tumour tissue was allowed to settle in the test-tube for 5 
minutes and the resulting supernatant was spun down at 200 g. The cell yield was 
subsequently determined. After fixation using 70% ethanol, aliquote containing 
106/ml cells were stained in phosphate buffered saline plus 1 mM EDTA contai­
ning propidium iodide (40 μg/ml, Calbiochem) and 100 μΐ RNase (1 mg/ml). The 
cell suspensions were filtered through a 50 μιη nylon mesh, incubated for 10 
minutes at 370C and measured with FCM (Ortho Diagn, MA; system 30 H). 
Propidium iodide stained human lymphocytes were used for optical alignment of 
the FCM apparatus. The amplifier gain setting was adjusted until the stained 
human lymphocytes (diploid) fell in channel 100 on a 512 channel scale. 
Generally 25,000 cells were measured per histogram. The coefficient of variation 
(CV) of the standard was approximately 2% and varied between 2 and 5.5% for the 
tumour cells. The CV was calculated as follows: Full width (mm) at half maximum 
peak height divided by distance (mm) of peak channel to origin of histogram. This 
is multiplied by 42.5. 
The modal DNA content, expressed as a DNA index (DI), is the ratio between the 
peak channel number of the aneuploid peak and that of the euploid peak of the 
same sample. 
From each passage 3-5 tumours grown in different mice were tested. 
3. 5. DNA image cytometry 
In addition to DNA flow cytometry, DNA image cytometry was applied on 
selected parts of the xenografts according to the method introduced by Oud et al. 
(33). This method which has been extensively described elsewhere (33-35), allows 
the analysis of the DNA content on paraffin-embedded tissues. In short, fifty 
micron sections of formaldehyde fixed, paraffin embedded xenografts were 
dewaxed and subsequently rehydrated. Guided by adjacent hematoxylin-eosin 
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Table 3.11. Take rate and initial lag phase of squamous cell carcinomas of the head and neck region in nude mice. 
Tumour 
A. HN-13 
B. HN-14 
С HN-15 
D. HN-16 
Percentual take rate 
1st Passage 
60% 
40% 
40% 
20% 
1) 
Subseq. 
100% 
80% 
100% 
60% 
Pass. 
Initial lag-phase 
1st Passage 
3-4 weeks 
4-6 weeks 
4-5 weeks 
16 weeks 
2) 
Subseq. Pass. 
1-2 weeks 
2-3 weeks 
1-3 weeks 
6-8 weeks 
1) Niunber of takes in relation to the number of mice transplanted. 
2) Time needed for the tumour to obtain a general mean diameter of about 4 mm. 
stained 5 μιη sections the tumour tissue was selectively dissected from the thick 
section, using a dissecting microscope and subsequently incubated in PBS (pH 7.4) 
containing 0.1% protease at ЗТС for 60 minutes. Incubation was terminated by the 
addition of 5 ml cold (40C) PBS. The isolated nuclei were washed twice in PBS by 
intermediate centrifugation steps and counted with a Coulter counter. About 
30,000 nuclei were spun down and resuspended in 200 μΐ fetal bovine serum. 
A monolayer smear was prepared on a glass slide using a cytocentrifuge, air-dried, 
and subsequently fixed in a mixture containing methanol, formaldehyde and acetic 
acid (85:10:5 by volume) for 1 hour. 
The nuclei were stained with pararosanilin (36) and the DNA content of 200 
stained nuclei was measured using the CAS 100 system (37). Normal human cells 
were used as a control. 
4. Results 
Four primary untreated squamous cell carcinomas of the head and neck region and 
their successfully transplanted tumour lines, passed to 3 and more subsequent 
passages, could be investigated. The characteristics of these tumours and their 
growth behaviour in nude mice are shown in Tables 3.1 and 3.II 
The take rate percentage related to the number of tumour inocula used, varied 
from 20 to 60% in the first passage and from 60 to 100% in the subsequent 
passages. The initial lag phase (the time needed for the tumour to obtain a general 
mean diameter of about 4 mm (10) varied between 3 and 16 weeks for the first 
passage and between 1 and 8 weeks in subsequent passages. 
The primary tumours contained in addition to tumour cells a varying amount of 
stroma with inflammatory cells (Fig.3.1). The xenografts grew as lobulated 
tumours surrounded by a fibrous capsule. During serial passaging the amount of 
stroma gradually diminished. In the tumour mass, thin connective tissue septa 
containing capillaries were present (Fig. 3.1). Immunostaining of cryostat sections 
with the monoclonal antibody MECA-20 directed against mouse endothelium 
revealed a positive reaction in the vascular endothelium (Fig.3.2) indicating the 
mouse origin of the stroma. At a volume of more than 50 mm3, the central areas of 
the tumours showed an increasing amount of keratin and/ or cellular debris. The 
xenografts retained the basic characteristics of their original tumours, with respect 
to both type and grade. None of the tumours showed local infiltration or haemato-
genous spread. 
The histological picture of the xenografts closely resembled the parent tumours, as 
is illustrated for tumour A in fig. 3.1. . DNA flow cytometry is a reliable and rapid 
method to establish the DNA profiles of the tumours during serial passaging. 
The flow cytometric DNA profiles of the primary tumour and the xenografts until 
the sixth passage of tumour A, are shown in fig. 3.3. The primary tumour showed a 
large peak of euploid cells and a smaller peak of aneuploid cells. 
The tumour xenograft showed a comparable histogram in the first passage. In sub­
sequent passages, the tetraploid peak and the G2/M peak became more predomi­
nant while the euploid peak decreased. This persisted up to the sixth passage and 
no difference was found between the DNA index (2.0) of the primary tumour and 
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Figure 3.1. Micrographs of the original tumour A (A) and after the second passage in 
nude mice (B), showing comparable histologic features. (Haematoxylin-eosin; χ 185). 
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Figure 3.2. Immunohistochemical staining of xenograft, showing exclusive staining of 
vascular endothelium with the antibody MECA-20, specifically directed against mouse 
endothelium (x 90). 
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Figure 3.3. DNA histograms of tumour A. Flow cytometry was performed on the original 
tumour (0), the first (1), second (2), and sixth (6) passage in nude mice. The peak at 
channel 100 represents euploid cells. 
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Figure 3.4. DNA histograms of tumour B. Flow cytometry was performed on the original 
tumour (0), the first (1), second (2), and sixth (6) passage in nude mice. The peak at 
channel 100 represents euploid cells. 
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Figure 3.5. DNA histograms of tumour С. Flow cytometry was performed on the original 
tumour (0), the first (1), third (3) and sixth (6) passage in nude mice. The peak at channel 
100 represents euploid cells. 
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Figure 3.6. DNA histograms of tumour D. Flow cytometry was performed on the original 
tumour (0) and the third (3) passage in nude mice. The peak at channel 100 represents 
euploid cells. 
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Figure 3.7. DNA image cytometric histograms of tumour tissue dissected from the xeno­
grafts of tumour А (12л passage, A) and tumour В (IO* passage,B). The histograms show 
the exclusive presence ofaneuploid cells (2). (1) indicates the position of normal cells, (4) 
the position ofGT/M. cells 
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the xenografts. 
The histogram of primary tumour В demonstrated a small euploid and a large 
aneuploid DNA stem line with a DNA index of 1.8. At the first passage in nude 
mice, the proportion of euploid cells was severely reduced, while the aneuploid 
peak was virtually unaffected. This picture did not change in subsequent passages 
(Fig.3.4). 
Flow cytometric analysis of primary tumour С showed a large proportion of 
euploid cells at channel 100 and a very small peak at about channel 200. During 
passaging in n u d e mice, the proportion of euploid cells and aneuploid cells 
changes in favour of the aneuploid portion (Fig.3.5). The DNA index of 2.2 was 
maintained during serial passaging. 
The original tumour D had a large aneuploid peak and a smaller euploid peak. The 
DNA histogram of the xenograft at the third passage revealed a persisting high 
proportion of aneuploid cells, but a considerable decrease in the proportion of 
euploid cells. The DNA index (1.65) was found to be the same for the primary 
tumour and the xenograft (Fig.3.6). 
It appeared that with DNA-flow cytometry no clear discrimination could be made 
between normal mouse cells and euploid human cells, because the DNA content of 
these species only slightly differs. For further identification of the euploid cells 
DNA image cytometry was applied on dissected tumour tissue, obtained from 
specimens embedded in paraffin. DNA image cytometric histograms of all four 
tumours studied revealed the exclusive presence of aneuploid cell populations as 
shown in Fig.3. 7 for tumours A and B. The DNA index of all four tumours did not 
differ significantly from that established with DNA flow cytometry. 
5. Discussion 
In this study four tumour lines of human squamous cell carcinoma of the head and 
neck region were successfully established in the nude mouse. It appeared that the 
initial lag-phase (the parameter for growth (10)) of all tumour lines decreased after 
the first transplantation while the take rate improved. In subsequent passages 
these parameters remained stable, but the differences between the individual 
tumours were maintained. 
The xenografts retained the histomorphological features of the original tumours 
with respect to both type and grade. 
These findings generally support the findings made in a previous study on xeno­
grafts of head and neck squamous cell carcinomas (10) and on xenografts of a large 
variety of other tumours (2-9). 
DNA cytometry showed that all the primary tumours contained both euploid and 
aneuploid cells. During passaging in nude mice all the tumours retained their 
original DNA index, which is in line with the observations made in human ovarian 
carcinoma, osteosarcoma and renal cell carcinoma (23-25). Only incidentally some 
xenografted tumours have shown instability of the DNA content during longterm 
xenotransplantation (24, 25). 
During passaging tumours A,B,C and D revealed a distinct decrease in the relative 
proportion of euploid cells, while the proportion of aneuploid cells increased. 
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A comparable dominance of aneuploid cells has been reported by Wennerberg (21) 
and van Haaften-Day et al. (38) after transplantation of tumours showing a 
bimodal DNA distribution with DNA flow cytometry. Wennerberg (21) reported 
the complete disappearance of the euploid tumour cell population from three 
mixed euploid and aneuploid head and neck squamous cell carcinomas after xeno-
grafting in nude mice. Comparable observations have been made by van Haaften-
Day et al (38) with ovarian tumours. It was suggested from both studies that a 
selection of aneuploid cells had taken place. This was assumed to be due to a 
higher growth rate or better metabolic adaptability of the aneuploid tumour cells 
to culture conditions in nude mice. 
This phenomenon deserves further consideration. Generally, little attention has 
been paid to the character of the euploid cell population in solid tumours with a 
bimodal DNA distribution. Although the diploid cells can represent an additional 
tumour clone, most authors assume that the euploid component is usually 
composed of normal host cells (23, 39-41). To differentiate between normal human 
host cells and euploid tumour cells routine DNA flow cytometry alone is inade-
quate and other cytological parameters are needed to solve this problem. After 
transplantation of tumours containing both euploid and aneuploid cell populations 
in nude mice, the characterization of the euploid cells is further complicated by the 
presence of ingrown stroma cells. Immunohistochemistry with the antibody 
MECA-20 clearly showed that these cells are of mouse origin. 
Normal mouse cells have a DNA content close to that of human cells and because 
the CV ranged between 2 and 5.5% the mouse cells could not visualized as a 
separate populat ion in the presented his tograms. The present DNA image 
cytometry analysis on different xenografts, without significant contamination of 
stroma cells, convincingly demonstrates that all tested tumours contain only 
aneuploid tumour cells. Therefore the euploid peak in the DNA histograms of the 
xenografts can be concluded to represent normal mouse stroma cells. The observed 
variation in the relative proportion of mouse cells must be ascribed to the varying 
amount of stroma cells in the different specimens. 
These observations advocate a careful analysis of the euploid cell population in 
order to decide on the presence of only benign host cells or benign and malignant 
euploid cells. 
Although the number of tumours tested is limited, this study appears to confirm 
that in accordance with the observations made in other tumours both histological 
features and DNA content of head and neck squamous cell carcinoma remain 
stable during serial passaging in the nude mouse. 
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CHAPTER IV. 
CHEMOSENSmVITY TESTING OF 
XENOGRAFTED SQUAMOUS CELL CARCINOMAS OF 
THE HEAD AND NECK REGION. 
This chapter has been submitted for publication: 
Elprana D, Kuijpers W, Wagener DJTh, Wessels JMC and van den Broek P. 
1. Abstract 
Eight squamous cell carcinomas from the head and neck region were established 
as xenograft lines in nude mice and tested for their sensitivity to the antineoplastic 
drugs bleomycin and cisplatin. Tumour volume, histology, DNA flow cytometry 
and mitotic activity were used as parameters. 
One out of the 8 tumours appeared to be highly sensitive to bleomycin, while three 
other hunours were sensitive to both bleomycin and cisplatin. These observations 
are in good correlation with the reported data in patients. 
All chemosensitive tumours showed regrowth after the cytotoxic drug treatment 
had been completed. No change was seen in the chemosensitivity or other features 
of the regrown tumours not even after repeated exposure to the drugs. 
Comparison of the tumour volume with the other parameters applied, indicated 
that the tumour volume of squamous cell carcinomas was not always a reliable 
parameter for testing chemosensitivity because of the considerable contribution of 
keratin to the tumour volume. It is concluded that additional parameters such as 
histological examination, DNA flow cytometry or mitotic activity, are necessary in 
order to draw reliable conclusions on xenografts with a large avital component. In 
addition, DNA flow cytometry has proved to be very useful for the rapid screen-
ing of drug sensitivity. 
2. Introduction 
Tests to predict the drug sensitivity of hunours outside the patient include both in 
vitro culture tephniques and xenografts in immunologically incompetent labora-
tory animals. 
Good correlations for some of the in vitro assays have been reported between in 
vitro chemosensitivity and the patient's response (1). However, the disadvantage 
of this approach is that the tumour cells are cultured in an artificial environment 
and lack the influence of the host's metabolism, while the pharmacokinetic proper-
ties of the drugs are not reflected in the therapeutic outcome. Although metabo-
lism and pharmacokinetics will differ in some respects in xenogeneic hosts, the 
results of drug testing of tumours grown in these hosts may be assumed to have 
more clinical relevance. 
From all xenogeneic hosts the athymic nude mouse has received the most interest 
since its introduction by Rygaard and Povlsen (2) as a model for studying the 
behaviour of human tumours and for testing antineoplastic drugs (3). 
Xenografts of a large variety of tumours can be succesfully grown in this animal 
throughout many generations, without any significant changes in the tumour 
characteristics (4-8). 
The main drawback of this animal model is that a direct comparison between the 
chemosensitivity of a xenograft and the patient is limited, because of the long 
delay between establishing the xenografts and drug testing. In addition, the 
activity of methotrexate, shown to be very effective on head and neck squamous 
cell carcinoma, was less pronounced on xenografts than could be expected from 
clinical studies (9). 
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Despite these limitations, this model has proved to be valid in retrospective 
studies and as a predictive system for testing new cytotoxic drugs (5,9-17). 
The criteria for evaluating the effects of anticancer drugs on xenografts have not 
yet been standardized. The evaluation is mainly based on changes in the tumour 
volume (5), tumour growth delay (18) or the life span of the animal (19). Cell cycle 
disturbances have been used incidentally as parameters (20-22), but histological 
observations have only rarely been performed (23). 
We evaluated the effect of cisplatin and bleomycin therapy on xenografts of 8 
squamous cell carcinomas from the head and neck region using the parameters: 
tumour volume, histology, DNA cytometry and labeling index. These two antineo­
plastic drugs have been shown to be effective for the treatment of these carci­
nomas (24). 
3. Materials and Methods 
3. 1. Tumours 
We studied 8 heterotransplanted squamous cell carcinomas from the head and 
neck region, which had been transplanted through a varying number of passages 
(Table 4.1.). The procedure for serial transplantation in n u d e mice has been 
described in detail elsewhere (7). Briefly, the tumour grafts were removed under 
ether anaesthesia and cut into pieces of about 1-2 mm3. These tissue fragments 
were implanted subcutaneously into the flanks of about 30 nude mice (weight 
about 20 g). Tumour growth was measured using a Vernier caliper at weekly 
intervals or more frequently in the case of rapidly growing tumours. The tumour 
volume was calculated as 0.5 χ the product of the three dimensions and was 
plotted on a linear scale (25). 
3. 2. Chemotherapy 
To study the effect of cytotoxic drugs on tumour growth, tumour bearing animals 
were randomized into control and treatment groups, consisting of about 10 
animals each. The treatment groups received either bleomycin or cisplatin at a 
maximum tolerated dose, while the control groups received a saline injection. 
Bleomycin (Lundbeck) was dissolved in water and injected subcutaneously into 
the back of the mice. The animals were treated with a total dose of 100 mg 
bleomycin, administered at a dose rate of 25 mg every two days. Cisplatin (cis-
dichlorodiamino-platinum) (Bristol Meyers) was dissolved in water immediately 
before intraperitoneal injection. The animals received a total dose of 12 mg/kg 
body weight, administered as a single dose of 3 mg/kg every two days. Treatment 
was initiated about 3-5 weeks after transplantation when the tumours had reached 
a size, which varied between 100 and 300 mm5. 
3. 3. DNA flow cytometry 
For flow cytometry (FCM), tumour tissue was minced with a scalpel and washed 
twice in Hank's balanced salt solution. The tissue was subsequently suspended in 
Eagle's minimal essential medium (MEM) containing collagenase (2mg/ml, type 
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Table 4.1. Chemosensitivity of xenografts of head and neck squamous cell caranomas. 
Tumour 
l.HN-4 
2. HN-6 
3.HN-9 
4.HN-2 
5. HN-2M 
6. HN-13 
7. HN-15 
8. HN-14 
Origin 
Piriform sinus 
Tongue 
Supraglottic 
Epiglottic 
Lymph node metast. 
ofHN-2 
Flour of the mouth 
Trigonum retromol. 
Epiglottis 
Stage 
T2N1M0 
T2N0MO 
T3N0M0 
T2N1M0 
T2N1M0 
T2N0M0 
T2N1M0 
T1N1M0 
Histology 
Mod. diff., 
keratinizing 
Mod. to well diff., 
keratinizing 
Mod. to well diff., 
keratinizing 
Mod. diff., 
keratinizing 
Mod. diff., 
keratinizing 
Mod. to well diff., 
keratinizing 
Mod. to well diff., 
keratinizing 
Mod. to well diff., 
keratinizing 
Initial 
lag 
phase 1) 
1-4 wks. 
1-4 wks. 
1-2 wks 
2-4 wks. 
3-5 wks. 
1-2 wks. 
1-3 wks. 
2-3 wks. 
DNA 
index 2) 
1.6 
1.8 
1.0 
1.6 
2.4 
2.0 
2.2 
1.8 
Chemosensitivity 
Bleomyc. Cispl 
+ + 
+ 
+ + 
+ + 
-
1) Time needed to obtain a mean diameter of 4 mm during serial passaging. 
2) DNA-index is defined as the ratio between the channel number of the aneuploid peak and that of the diploid peak of the 
same sample. 
II, 132 U/mg: Cooper biomedical) and hyaluronidase (0.5 mg/ml, type I, 370 
U/mg; Sigma) and incubated under agitation for 1 hour at ЗТ'С. After the tissue 
suspension had settled, the supernatant was discarded and the tissue was 
incubated in Hank's balanced salt solution, containing trypsin (0.25 mg/ml) and 
dithioerythritol (3 mg/ml) overnight at 40C. The suspension was spun down at 200 
g and the pellet was resuspended in 4 ml MEM, supplemented with 10% heat-
inactivated fetal bovine serum (FBS, Gibco, Europe) and 100 μΐ RNase (2.5 mg/ml) 
and incubated for 30 minutes at ЗТ'С under mild agitation. After centrifugation of 
the supernatant at 200 g, the cells were fixed in 70% ethanol. 
Aliquots of 10* cells/ml were stained in phosphate buffered saline (PBS) contai­
ning 1 mM EDTA, propidium iodide (40 μg/ml; Calbiochem) and 100 μΐ/ml 
RNase (1 mg/ml) for 10 minutes at 370C and subsequently filtered through a 50 
ц т nylon mesh. The DNA content was measured using flow cytometry (Ortho 
Diagn, MA; system 30 H). Human lymphocytes stained with propidium iodide 
were used for optical alignment of the FCM apparatus. The amplifier gain setting 
was adjusted until the (diploid) lymphocytes fell in channel 100 on a 512 channel 
scale. Generally, 25,000 cells were measured per histogram. The coefficient of 
variation (CV) of the standard was approximately 2% and varied between 2 and 
5.5% for the tumour cells. DNA flow cytometry was carried out on the xenografts 
during the pretreatment period and repeated 1, 2, 3 and 4 weeks after the start of 
the treatment with cytotoxic drugs. 
The modal DNA content, expressed as a DNA index, was defined as the ratio 
between the channel number of the aneuploid peak and that of the euploid peak of 
the same sample. 
3. 4. DNA image cytometry 
Formalin-fixed, paraffin embedded tumours were used for image cytometry. This 
method has been described in detail elsewhere (26). Briefly, 50 μιη sections were 
dewaxed with xylene and rehydrated. Guided by adjacent haematoxylin-eosin 
stained sections, the tumour tissue was dissected and incubated in PBS, containing 
0.1% protease for 1 hour at ЗТ'С. The isolated nuclei were washed twice in PBS 
and counted with a coulter counter. Approximately 30,000 nuclei were spun down 
and resuspended in 200 μΐ fetal bovine serum. A monolayer smear was prepared 
on a glass slide, using a special centrifugation bucket. The slide was air dried and 
fixed in a mixture containing methanol, formaldehyde and acetic acid (85:10:5 
v/v) for 1 hour. The smears were stained with pararosanilin and the DNA content 
of 200 nuclei was measured using the CAS system. Normal human cells were used 
as a control. 
3. 5. Histology and autoradiography 
For the histological studies, the entire xenografts were fixed in phosphate buffered 
(0.1M; pH 7.4) formaldehyde (4 %) and embedded in paraffin. Sections (7 μιη) 
were stained with haematoxylin-eosin. 
To evaluate the effect of the cytotoxic drugs on DNA synthesis, animals in both the 
control and treatment groups received an intraperitoneal injection of 3H-thymidine 
( ^ C i / gram body weight; S.A. 2Ci/mM, Radiochemical centre, Amersham, 
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England). All the animals were injected at 10.00 a.m. to avoid diurnal variations . 
The animals were killed by decapitation one hour later and processed as described 
above. Sections (7 μιη) were mounted on gelatinized slides and coated with Ilford 
G5 emulsion using the dipping technique (27). After an exposure time of 4 weeks 
the sections were developed, fixed and stained with haematoxylin-eosin. 
A total of 1,000 tumour cells were counted at 4 different sites in each xenograft. 
The labeling index was expressed as the number of labeled cells per 100 cells 
counted. 
4. Results 
4. 2. Untreated tumours 
4. 1.1. Growth behaviour 
The xenografted tumours grew as circumscribed, often lobulated tumours, sur­
rounded by a fibrous capsule. In two tumours, infiltration of tumour cells into the 
capsule was observed. No distant metastases were found. All the xenografts 
displayed an increasing amount of necrosis and/or accumulation of keratin or 
parakeratotic lamellae in the central part of the lobules within a few weeks after 
transplantation. During serial passaging all the tumours showed a stable growth 
pattern, i.e. the time needed for the tumour to reach a mean diameter of about 
4mm defined as the initial lag-phase (7) (Table 4.1). The histological features of the 
primary tumours appeared to have been retained. 
The mitotic activity of tumours HN-4, HN-6 and HN-9 was determined using 3H-
thymidine. No great differences between the labeling indices of the tested tumours 
were observed. The labeling index was found to be rather stable throughout the 
observation period between 3 and 14 weeks after transplantation (Table 4.II). 
4.Ί.2. DNA cytometry 
DNA flow cytometry of the various tumour lines showed an euploid and an 
aneuploid peak in all tumours except for tumour HN-9 which displayed only a 
single euploid peak. The DNA indices are listed in Table 4.1. 
DNA image cytometry of the dissected parts of the xenografts revealed that the 
euploid peak of the tumours with a bimodal DNA distribution represented normal 
mouse cells, as illustrated by tumour HN-13 in Fig. 4.1. The tumour which showed 
only an euploid peak with DNA flow cytometry (HN-9), was found to contain 
only euploid tumour cells. 
4. 2. Effect of cytotoxic drugs 
The effects of bleomycin and cisplatin on xenografted squamous cell carcinoma of 
the head and neck region in nude mice are summarized in Table 4.1. Three 
tumours (HN-4, HN-13 and HN-15) were found to be sensitive to both drugs, 
while one tumour (HN-6) was only sensitive to bleomycin. The remaining four 
tumours (HN-9, HN-2 and its lymph node metastasis HN-2M and HN-14) were 
not sensitive to either of the drugs. 
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Table 4.11. Incorporation of ЗН-thymidine (labeling index; mean ± SD) in xenografts at 
various times after start of drug administration. 
Tumoui 
HN-4 
HN-4 
HN-6 
HN-6 
HN-6 
HN-6* 
HN-6* 
HN-9 
HN-9 
HN-9 
Drug 
Contr 
Cispl 
Contr 
Cispl 
Bleom 
Contr 
Bleom 
Contr 
Cispl 
Bleom 
start 
treatment 
28.6 ±3.8 
21.7 ±2.7 
19.7 ±0.6 
24.9 ±3.3 
10 days 
after 
start 
25.5 ±4.0 
0.0 ±0.0 
30.0 ±2.6 
0.0 ±0.0 
19.9 ±2.2 
0.0 ±0.0 
20.1 ± 0.7 
21.4 ±8.7 
29.9 ± 4.3 
4 weeks 
after 
start 
27.0 ±5.1 
23.9 ±3.2 
21.3 ±2.8 
22.4 ± 4.6 
28.7 ±4.2 
23.6 ±3.9 
22.0 ±1.1 
24.0 ±0.4 
9 weeks 
after 
start 
26.4 ± 1.2 
24.5 ±4.7 
20.0 ±2.8 
16.0 ±2.4 
20.9 ±2.0 
23.913.4 
20.3 ± 3.4 
19.0 ±3.2 
21.2 ±4.8 
* Tumours raised from cells of tumour HN-6, which regrew after first treatment 
with bleomycin. 
В 
D l l t n b u t i o n of DNA-Maas 
С 20 
Figure 4.1. DNA cytometry of xenografts of tumour HN-13 (4" passage). A. DNA flow 
cytometry (arrow indicates euploid cells at channel 100 ); B. DNA image cytometric 
histogram of dissected tumour cells, showing the exclusive presence ofaneuploid tumour 
cells (2). (1) indicates the position of euploid cells; (4) indicates position oftetraploid cells. 
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4.2.1. Growth curves 
A sharp decrease, starting during the first week and leading to nearly complete 
regression of the tumour was observed in the growth curves of tumours HN-4 
and HN-13 within 4 to 5 weeks after the start of cisplatin treatment. This was 
followed by gradual regrowth of the tumours. This is shown for tumour HN-4 in 
figure 4.2.A. The same patterns were also observed for these tumours after 
exposure to bleomycin. 
The growth curves of tumours HN-6 and HN-15 flattened out after exposure to 
bleomycin, but 4 to 5 weeks after the completion of drug treatment, the tumour 
volume gradually increased as shown for tumour HN-6 in figure 4.2.C. The 
growth curves of tumour HN-15 showed a comparable behaviour after cisplatin 
treatment, but this drug did not have any effect on the growth curves of tumour 
HN-6. 
The growth curves of tumours HN-9, HN-2, HN-2M and HN-14 did not show any 
change after treatment with cisplatin or bleomycin in comparison with the control 
group of the same tumours. There were no changes in the response of drug sensiti-
vity testing during the various passages up to the 12th passage. In addition, the 
xenografts established from tumour cells (HN-4 and HN-6), which regrew after 
one, two and three courses of treatment with cytotoxic drugs, did not show any 
change in their drug sensitivity or growth pattern, as shown in Fig. 4.2.B and D. 
4. 2. 2. Histology 
Histological examination of the different tumours at the start of drug exposure 
showed circumscribed, occasionally lobulated tumours, surrounded by a fibrous 
capsule. The tumours consisted of a varying amount of vital tumour cells and 
dead material, which was composed of cellular debris, dyskeratosis or keratin 
lamellae. The composition of this material differed between the various tumour 
lines. Examples are given in Figs. 4.3 A and 4.4 A. 
Histological examination of the sensitive tumours demonstrated vacuolisation and 
cytolysis of the tumour cells, which lead to profound degeneration of the major 
part of the tumour cells between 1 and 2 weeks after the start of drug exposure. At 
two weeks, the tumours were mainly composed of dead material. In tumours HN-
4 and HN-13 this material consisted of cellular debris, dyskeratosis and fluid sur-
rounded by a fibrous capsule of varying thickness (Fig. 4.3 B). The stroma showed 
severe infiltration by inflammatory cells (Figs. 4.3 B, C; 4.4 B, C). Scattered tumour 
cells could be found in and on the inner side of the fibrous capsule (Figs. 4.3 C; 4.4 
C). In tumours HN-6 and HN-15 the dead material mainly consisted of keratin 
lamellae (Fig. 4.4 B). Between two and three weeks onwards, the number of 
tumour cells started to increase, initially mainly in the peripheral part of the 
tumours (Figs. 4.3 D; 4.5 A, B). This finally resulted in complete regrowth of the 
tumours. In tumours HN-4 and HN-13 tumour regrowth was associated with an 
increased proliferation of fibrous tissue (Fig. 4.3 D). 
4. 2. 3. Labeling index. 
The injection of 3H-thymidine after drug administration, revealed a fast decrease 
in the number of labeled cells to zero between one and two weeks in tumours HN-
4 and HN-6 after treatment with cisplatin and bleomycin, respectively. Four weeks 
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— weeks 
Figure 4.2. Typical examples of the effects ofcisplatin administration on growth curves of 
xenografts of tumour HN-4 (A) and of bleomycin on HN-6 (C), showing two different 
types of curves. Growth curves В and D represent the effect of drug administration on 
xenografts raised from the tumour cell population regrovm after three successive treat­
ments. Arrow indicates the start of drug injection, c: untreated xenografts. 
Figure 4.3. Micrographs of xenografts of tumour HN-4, before (A) and 2 weeks (B) and 4 
weeks (D) after the start ofcisplatin administration. С higher magnification ofB, showing 
scattered tumour cells. Regrowth of tumour is visible in D. (Haematoxylin-eosin; A, CD: χ 
185; Β: χ 20). *" 
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Figure 4.4. Micrographs of xenografts of tumour HN-6, before (A) and 2 weeks (B) after 
the start of bleomycin administration. С higher magnification ofB, showing accumulated 
keratin lamellae and fibrous capsule. (Haematoxylin-eosin; A,C: χ 185; Β: χ 20). 
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Figure 4.5. Survey (A) and higher magnification (B) of xenograft of tumour HN-6, four 
weeks after the start ofbleomyrín administration, showing regrowth of the tumour on the 
inner side of the fibrous capsule. (Haematoxylin-eosin; A: χ 15; Β: χ 100). 
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after the start of drug administration, the labeling-index of the regrown tumours 
had returned to the pretreatment level (Table 4.II). Comparable observations were 
made when a xenograft of tumour HN-6, raised from a regrown cell population of 
cells after the first treatment with bleomycin, was treated with bleomycin. The 
labeling indices of the tumours, which according to their growth curves and 
histology did not respond to cisplatin (HN-6 and HN-9) or bleomycin (HN-9) did 
not significantly differ from the control values (Table 4.II). 
4. 2. 4. DNA flow cytometry 
The DNA histograms of the xenografts, which according to their growth curves 
and histology were found sensitive to cisplatin or bleomycin (HN-4, HN-6, HN-13 
and HN-15) showed a sharp decrease in the aneuploid peak and the G2/M peak 
one week after the start of drug administration, while there was a relative increase 
in the proportion of the mouse stroma cells. Depending on the tumour line, the 
DNA histograms regained their pretreatment profiles between two and four 
weeks after the start of drug exposure (Figs. 4.6, for example tumours HN-13 and 
HN-15). A similar course was observed for the tumours raised from the regrown 
tumours which were treated for a second and a third time. 
No changes were seen in the DNA histograms of the tumours which were found 
to be insensitive to treatment by bleomycin (HN-2, HN-2M, HN-9 and HN-14) or 
cisplatin (HN-2, HN-2M, HN-6, HN-9 and HN-14) (Figs. 4.7, for example tumours 
HN-9 and HN-14). 
5. Discussion 
Human tumour xenografts grown in nude athymic mice form a valuable model 
for studying tumour behaviour and testing antineoplastic drugs. 
In the present study, 8 human squamous cell carcinomas from the head and neck 
region, established as xenograft lines in nude mice, were tested for their sensitivity 
to cisplatin and bleomycin using different parameters. The results showed that 1 
out of the 8 xenografts was highly and selectively sensitive to bleomycin (HN-6). 
Three tumours (HN-4, HN-13 and HN-15) were sensitive to both drugs and the 
remaining four tumours (HN-9, HN-2, HN-2M and HN-14) were not sensitive to 
either of the drugs. These conclusions were drawn on the basis of histological exa­
mination, the growth curves and DNA flow cytometry. This was further substan­
tiated by the study of the incorporation of 3H-thymidine in three tumours. No cor­
relation was found between the chemosensitivity and the degree of differentiation, 
which is in agreement with the observations made in tumours from other origins 
(28,29). 
The present observations are also in line with clinical response with these drugs. 
Partial or complete regression has been observed in the same order of magnitude 
(30,31) while differential sensitivity for either cisplatin or bleomycin has been esta­
blished. 
The differential sensitivity is in agreement with the scarce available data on che­
mosensitivity testing on xenograft lines of head and neck squamous cell carci­
nomas, performed by Sneeuwloper et al. (32) and Azar et al. (33). Remarkably, 
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Figure 4.6. DNA histograms of xenografts of tumours HN-13 and HN-15 at various times 
after the start of drug administration. The tumours are sensitive to both cisplatin and 
bleomycin. 
Tumour HN-13: A. control; B. cisplatin 1 week; С àsplatin 3 weeks; D. bleomycin 1 week; 
E. bleomycin 2 weeks. 
Tumour HN-15: F. control; G. cisplatin 1 week; H. cisplatin 2 weeks; I. bleomycin 1 week; 
J. bleomycin 2 weeks. 
(arrows indicate euploid cells at channel 100 ) 
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Figure 4.7. DNA-histograms of xenografts of tumours HN-9 and HN-14 at various times 
after the start of drug administration. These tumours are insensitive to both rísplatin and 
bleomyrín. Tumour HN-9: A. control; B. rísplatin 1 week; С bleomycin 1 week. 
Tumour HN-14: D. control; E. rísplatin 1 week; F. rísplatin 2 weeks; G. bleomycin 1 week; 
H. bleomycin 2 weeks. 
( arrows indicate euploid cells at channel 100). 
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Braakhuis et al. (9) reported sensitivity to both drugs in 6 out of 7 xenograft lines 
tested, using the tumour volume as an evaluation parameter. This is a high sensiti-
vity rate in comparison with the present data and the clinical observations 
reported by Taylor (34). However, there was wide variation in the sensitivity of 
the different lines. When they omitted the tumours with only a minimal change in 
the tumour volume, a close correlation with the clinical findings could be found. 
In the present study, two types of growth curves could be distinguished after 
cytotoxic drug treatment. One type showed a sharp decrease in the tumour 
volume and can be considered to represent a strong response. The other type, 
showing a flattening of the curves, which can be considered to depict a moderate 
response or growth retardation, without any significant regression of the tumour 
volume. However, in both cases histopathological examination showed the nearly 
complete disappearance of tumour cells between one and two weeks after the start 
of drug treatment. A comparable observation was made with DNA flow cyto-
metry. The only difference observed was that in the tumours with the most 
marked response the central part of the xenografts contained a varying amount of 
fluid, cellular debris and dyskeratosis. The moderately responding tumours, 
however, showed in addition to cellular debris, the presence of a large mass of 
keratin lamellae surrounded by a fibrous capsule. These findings indicate that flat-
tening of the growth curve is related to the accumulation of keratin lamellae, 
which are more resistant to désintégration and resorption and prevent a further 
decrease in the tumour volume after the disappearance of the tumour cells. 
Although the volume is generally considered to be a useful parameter for the eva-
luation of drug sensitivity of tumour xenografts, the present findings indicate that 
drug-induced changes of the tumour volume are not always a true reflection of the 
response to drug treatment. If the sensitivity of the tumour is only moderate or 
low or if it contains both sensitive and insensitive populations of tumour cells, the 
question arises as to whether the tumour size is a reliable parameter for the 
response to treatment if a large amount of dead material is present. Therefore, the 
final evaluation of a tumour's response to cytotoxic drugs in xenografts has to be 
made in conjunction with histopathological examination. 
The DNA histograms of chemosensitive tumours showed distinct changes in the 
population of tumour cells within one week after the start of drug administration. 
These rapid changes in the DNA histograms of chemosensitive tumours, indicate 
that DNA flow cytometry may be very useful for the rapid screening of drug 
effects. 
All the sensitive tumours showed regrowth, usually within 2-3 weeks after 
treatment, although the maximum tolerated drug dose has been applied. The first 
signs of regrowth were detected by DNA flow cytometry and histological exami-
nation after 2-3 weeks, followed by a gradual increase in the tumour volume. 
The tumour cells which regrew were most likely the original tumour cells, which 
had escaped drug treatment. This can be concluded on the basis of the DNA 
indices of the tumours after regrowth which were similar to those of the control 
tumours and also on the labeling indices of the regrown tumours HN-4 and HN-6, 
which were not significantly different from the pretreatment levels. Moreover, 
these parameters were found to be the same after retransplantation of the regrown 
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cell population. Although tumour resistance has often been reported during 
patient treatment after previous cytotoxic drug therapy, to our knowledge, this 
phenomenon has been reported incidentally in xenograft lines of human tumours. 
Regrowth of effectively treated human tumour xenografts has been reported by 
Kyriazis et al. (23) in a comparable study. These authors suggested that this 
regrowth was caused by resistant tumour cell clones, although no further proof 
was given. Using a more convincing approach. Mattern et al. (35) studied the 
development of drug resistance in xenografts of an epidermoid lung carcinoma. 
They observed a great variation in the time course of the development of resi-
stance against the various drugs applied. Resistance to vincristin and actinomycin 
D was observed after one single treatment and was suggested to be due to the 
presence of a pre-existing subpopulation of cells, which were resistant to these 
drugs in the original tumour. Conversely, resistance to cisplatin did not become 
apparent until after the 4th treatment and it slowly progressed after subsequent 
treatments. This gradual development of tumour resistance against cisplatin has 
also been found in other xenografts (36,37). These observations might explain the 
absence of any change in the therapeutic response during 3 successive treatments 
in the present study 
Summarizing, this study shows that tumour volume, histology, 3H-thymidine 
incorporation and DNA cytometry can be used as parameters for evaluating drug 
response. Growth curves alone appear not to be a fully reliable parameter for the 
final evaluation of drug sensitivity, especially for tumours containing a substantial 
amount of dead material with low or moderate sensitivity. In these cases, addi-
tional parameters are needed. 
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CHAPTER V. 
A DEVICE FOR THE PRODUCTION OF FRESH TUMOUR 
SLICES FOR CYTOTOXIC DRUG TESTING 
This chapter has been published in: Tumor Biol 10:324-329,1989 by Иргапа D, 
Schwachöfer J and Kuijpers W. 
1. Abstract 
The potential suitability of thin slices of fresh tumour tissue for the in vitro testing 
of antitumour drugs was studied. 
With a simple device, sets of tumour slices of equal thickness were produced 
rapidly with minimal cellular damage. 
The sections showed a reproducible stable incorporation of 3H-thymidine for incu-
bation periods of more than 24 hours. 
Preliminary data on the effect of cytotoxic drugs on sections of xenografts of 
human squamous cell carcinoma, revealed a distinct correlation between their in 
vitro effects on 'H-thymidine incorporation and their in vitro sensitivity in nude 
mice. 
2. Introduction 
Over the past decade, studies on the development of in vitro assays for predicting 
the in vivo drug sensitivity of solid malignant tumours has been mainly focussed 
on the use of single cell suspensions both in short and long-term cultures (1-7). 
Although good correlation has been reported between some types of tumours and 
in vivo conditions, there is still no consensus that any of these tests are suitable for 
routine clinical use. 
One of the major limitations of these techniques is the preparation of representa-
tive suspensions of single viable cells. It has become clear from several studies that 
the disaggregation procedure used, either mechanical, enzymatic, chemical or a 
combined procedure, has great influence on the vitality, number and type of cells 
isolated (8,9). 
In order to overcome these problems, the use of tumour fragments or slices seems 
to be a good alternative. However, this technique has only been applied inciden-
tally for cytotoxic drug testing (10), presumably because of the problems encoun-
tered in obtaining comparable tissue fragments with equal proportions of repre-
sentative viable tumour cells, preferably from the same tumour region. 
The major advantage of this approach lies in the preservation of cell to cell and cell 
to matrix interactions. Moreover, serious cell damage caused by the disruption of 
intercellular connections which is especially pronounced in some epithelial 
tumours, can be prevented. In this report we describe a simple device for the rapid 
production of thin slices from fresh tumour tissue with a comparable number of 
viable tumour cells and their suitability for cytotoxic drug testing. 
3. Materials and Methods 
The construction of the device for the production of thin tumour slices is shown in 
Fig. 5.1. The device consists of four razor blades assembled in a stainless steel 
holder. The razor blades are approximated by stainless steel blades of 0.4 mm and 
bolted together. 
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Fig. 5. 1. Slicing device, consisting of 4 razor blades separated by stainless steel blades of 
0.4 mm 
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In this study, use was made of tumour xenografts obtained from established lines 
of human head and neck squamous cell carcinomas in nude mice (11). 
For slicing, part of the tumour, trimmed to an appropriate size, was submerged in 
tissue culture medium (MEM) in a Petri dish to avoid drying out. The blades were 
advanced through the tumour tissue using a single gentle stroke. In this way, sets 
of three tumour slices could be obtained. 
After loosening the bolts, the slices could easily be removed from between the 
blades with a fine camel hair brush and deposited in the tissue culture medium. 
The slices were subsequently transferred to small flasks containing 2 ml incubation 
fluid. Incubation was performed in RPMI1640 with 10% foetal bovine serum sup­
plemented with 2 mM glutamin/ml, 100 IU penicillin/ml and 100 μg strepto­
mycin/ml (Gibco Ltd., Paisly, Scotland) for various periods. 
For cytotoxic drug testing, either cisplatin or bleomycin were added to a final con­
centration of 10 and 5 μg/ml, respectively. 
During the last hour of incubation, 3H-thymidine (S.A. 2 Ci/mM, Radiochemical 
centre, Amersham, England) was added to the culture medium to a final activity 
of 1цСі/т1. As hyperbaric oxygenation has been shown to favour the uptake of 
Ή-thymidine in the deeper parts of the tumour slices (12) incubation was carried 
out under hyperbaric conditions (1.8 atm. Oj). 
After incubation the slices were washed in an isotonic solution of unlabelled 
thymidine for 3 hours at 4 ^ to remove any free 3H-thymidine and subsequently 
dissolved in Luma Solve (Lumac Systems AG, Basel, Switzerland). A LKB 81000 
Liquid Scintillation Counter was used to measure the 'H-thymidine incorporation. 
To determine the site of 3H-thymidine incorporation, the slices were fixed with 
neutralized formaldehyde (4%) after incubation and embedded in paraffin. 
Sections of 7 μτη were coated with Ilford K.5 emulsion and developed after an 
exposure time of 4 weeks. Staining was performed with haematoxylin-eosin. 
4. Results 
Sets of three slices of tumour tissue could be cut in rapid succession with the 
device. Without much practice, 5 sets could be obtained within 15 minutes. The 
wet weights of several sets of slices, obtained from a block of tumour tissue 
trimmed to an appropriate size, are summarized in Table 5.1. These data demon­
strate that the variation in weight between the different slices from each set are 
rather small. 
The autoradiograph in Fig. 5.2 shows the specific incorporation of 5H-thymidine 
into the nuclei of the tumour cells througout the whole slice. 
For measuring the inter-slice variation of 3H-thymidine incorporation, sets of three 
slices from the same tumour were used. The slices were incubated separately. The 
data obtained for one of the tumours, presented in Table 5.Π, show good compara­
bility between the amount of 'H-thymidine incorporated into each set of slices. 
An example of the incorporation of Ή-thymidme after various incubation periods 
is shown in Fig. 5.3. Incorporation, measured as cpm/slice, was expressed as a 
percentage of the value measured after one hour, which was set at 100%. It 
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Table 5.1. Wet weight of individual slices of 4 sets obtained from one block of tumour 
material. 
Set no. 
l a 
b 
с 
2a 
b 
с 
За 
b 
с 
4а 
b 
с 
Weight (mg) 
15.3 
16.7 
16.4 
10.2 
125 
9.8 
13.4 
12.8 
14.3 
14.8 
14.2 
13.7 
Average (± SD) 
16.110.7 
10.8 ±1.5 
13.5 ± 0.8 
14.2 ±0.6 
Table 5.II. 3H-thymidine incorporation in 4 sets of tumour slices, measured in cpm/slice. 
Different slices from each set were incubated separately to determine inter-assay 
variation. 
Set no. 
l a 
b 
с 
2a 
b 
с 
За 
b 
с 
4а 
b 
с 
cpm/slice 
7,354 
7,668 
7,475 
8,819 
8,676 
8,693 
9,117 
8,977 
9,228 
9,879 
9,798 
9,683 
Average (± SD) 
7,499 ±158 
8,748 ±101 
9,107 ±126 
9,787 ± 9 8 
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Fí^. 5. 2. Micro-autoradiograph of tumour slice incubated for 5 hours at 1.8 atm O2. 3H-
thymidine was added during the last hour of incubation. Note the specific incorporation of 
3H-thymidine in the nuclei of the tumour cells, distributed throughout the whole section. 
(Haematoxylin-eosin, χ 270). 
120 
RELATIVE CPM-VALUE (%) 
100-
18 24 36 48 60 72 
TIME OF INCUBATION (h) 
Fig. 5. 3. 3H-thymidine incorporation in tissue slices of tumour xenografi during increa­
sing incubation periods; cpm-values are expressed as a percentage of the value measured 
after 1 hour of incubation (11,748 cpm). 3H-thymidine was added during the final hour of 
incubation. 
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appeared that incorporation in time only slightly decreased during the first 24 
hours. The radioactivity subsequently decreased to about half of the original value 
during the next 48 hours. 
A preliminary study on 4 xenografts from different tumour lines, to investigate the 
feasibility of this method for cytotoxic drug testing was performed. The data 
revealed only a substantial decrease in the incorporation of Ή-thymidine in the 
tumours found to be sensitive to the same drugs in vivo in nude mice, as shown in 
Table 5.ΠΙ (13). 
Table 5.Ш. The effect ofcisplatin and bleomycin on the incorporation of'H-thymidine in 
slices of xenografts from 3 different squamous cell carcinomas of the head and neck and 1 
lymph node metastasis (HN-2M. lymph node metastasis of HN-2) after an incubation 
period of 24 hours.(Mean ± SD of3 slices). 3H-thymidine incorporation in control sections 
was set at 100%. 'H-thymidine was added during the final hour of incubation. 
* A comparable effect was found in vivo in nude mice with these drugs (refi 13) 
Tumour 
HN-2M 
HN-2 
HN-4 
HN-6 
Cisplatin* 
108.75127.50% 
85.0 ± 6.25% 
45.0 ±21.25% 
81.25 ± 25.0 % 
Bleomycin* 
93.75111.25% 
92.50112.50% 
38.75117.50% 
37.50117.50% 
5. Discussion 
The present study was undertaken to investigate the feasibility of using thin 
tumour slices to test cytotoxic drugs in vitro. Through the preservation of tissue 
integrity, this approach has the great advantage that artefacts, associated with the 
use of single-cell suspensions, are avoided. 
It was established that with the simple device presented, sets of comparable slices 
from fresh tumour tissue could be produced very rapidly without special skill. The 
tumour slices prepared in this way showed minimal cellular damage or metabolic 
disturbances, as can be concluded from the reproducible incorporation of 3H-
thymidine, which remained stable throughout an incubation period of at least 24 
hours. 
Especially the production of sets of serial slices which can be considered mutually 
comparable with respect to their cell population and Ή-thymidine incorporation, 
makes this method very suitable for cytotoxic drug testing. In this way, sections 
treated with drugs can be compared with an adjacent control section. 
The close correlation established between the effects of some antitumour drugs on 
slices of xenografted human squamous cell carcinoma and the in vivo response in 
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nude mice, justify the broader application of this approach on tumour specimens 
directly obtained from patients. 
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CHAPTER VI. 
CYTOTOXIC DRUG SENSITIVITY OF 
SQUAMOUS CELL CARCINOMAS AS 
PREDICTED BY AN IN VITRO TESTING MODEL 
This chapter has been published in: Anticancer Res 9:1098-1094,1989 by Elprana 
D, Schwachöfer J, Kuijpers W, van den Broek Ρ and Wagener DJTh. 
1. Abstract 
Two in vitro techniques for testing the chemosensitivity of squamous cell carci­
nomas from the head and neck were compared. 
Single-cell suspensions and tumour slices obtained from human xenografts were 
used. The sensitivity to cisplatin and bleomycin was quantified using the incorpo­
ration of Ή - thymidine as a parameter. The in vitro assays were compared with in 
vivo tests in mice. 
No reliable data could be obtained with cell suspensions of these tumours due to a 
rapid decrease in cell viability during incubation while tumour slices revealed a 
stable control level of 3H-thymidine incorporation for up to 30 hours. 
In 6 out of 7 cases close agreement was found between the effect of the cytotoxic 
drug on the tissue slices and on the same tumours in nude mice. 
2. Introduction 
Clinical experience has shown that treatment modalities which are effective for 
one tumour type are not necessarily effective for another, even tumours of the 
same type or histology exhibit wide variability in their response to cytotoxic 
agents. The development of predictive tests which can determine the sensitivity or 
resistance of malignant tumours to antineoplastic agents prior to therapy, has 
brought about a variety of testing systems (1). Both in vivo and in vitro assays 
have emerged, which apply different parameters to quantify tumour response to 
drugs. 
Each test has both advantages and disadvantages in terms of sensitivity, accuracy 
and financial feasibility. 
Although the subcutaneous implantation of human tumuor xenografts in athymic 
or immunosuppressed mice is fairly reliable with regard to its accuracy for predic­
ting the sensitivity to certain drugs (2,3,4), it will always be unsuitable for indivi­
dual patient testing due to its expensive and time-consuming character. 
An alternative in vivo method: the subrenal capsule assay, has been introduced by 
Bogden et al. (5). This method involves the implantation of solid pieces of tumour 
tissue under the renal capsule. Drug sensitivity can be tested within 6 days and the 
predictive data of this assay have produced promising clinical correlations (6), 
with an accuracy comparable with conventional subcutaneous implantation (7). 
From recent studies it has become clear that it is necessary to make histologic 
assessments of this model with regard to its suitability for predicting the effect of 
cytotoxic drugs (7,8). 
When employing in vitro predictive tests on human tumour cells, a number of 
general technical problems must be overcome, such as cell death, contamination, 
low growth rate and low plating efficiency. In particular the single-cell suspen­
sions which employ the incorporation of radioactive labeled nucleotide precursors 
(9) and the stem cell assay introduced by Hamburger and Salmon (10), which 
determines the reproductive capability of tumour cells, have proved to be 
potential tools for quantifying the drug sensitivity of human tumours. 
Although the human tumour stemcell assay is subject to a variety of artefacts, in 
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recent years there has been growing interest in its applicability in prospective 
clinical trials due to its potential capacity to predict drug resistance in certain 
tumour types (11,12). The routine selection of anticancer drugs is still premature, 
but being able to predict the resistance in 84-95% of the cases and drug sensitivity 
in 40-70% of the cases, seems promising (13). However, only a limited number of 
tumour types can be used effectively in the stemcell assay and only a subset of 
these, including breast, colorectal, kidney, lung and ovarian tumours and mela-
nomas, give rise to évaluable assays (14). 
To our knowledge, the stemcell assay is the only in vitro test to have been applied 
for testing the chemosensitivity of human head and neck tumours. In their study, 
Johns and Mills (15) showed that 49% of 73 squamous cell carcinomas demon-
strated clonal growth. They concluded that a high cloning efficiency correlates 
with a poor prognosis. This was contradicted by Mattox et al. (16) who failed to 
find such a correlation. The high rate of contamination, low growth rate and low 
plating efficiency were the main problems encountered. This led to the conclusion 
that a clonogenic assay does not contribute to the management of patients with 
cancer of the head and neck. In a recent study, it appeared that the different tech-
niques used for cell dispersion of this type of tumour have a great deal of in-
fluence on the quality of the cell suspension (17). This may be an underlying cause 
for the low plating efficiency. 
The present study deals with the in vitro testing of the chemosensitivity of human 
head and neck squamous cell carcinoma, using both cell suspensions and tissue 
slices. The results obtained in vitro were compared with the in vivo effects in nude 
mice. 
3. Materials and Methods 
3.1. Tumours 
The tumours used in this study were xenografts of human squamous cell carci-
nomas from the head and neck region, grown subcutaneously in nude mice 
(Balb/c, nu/nu). The origin and histological features of these tumours are shown 
in Table 6. I. The tumours were transplanted through 10-15 passages and were 
found to preserve their histological features (18). Apart from these xenografts, one 
original well-differentiated squamous cell carcinoma from the tongue (T4M3M0) 
was used. 
3.2. Testing ofantitumour drugs 
3.2.1. Cell suspensions 
Tumour tissue, obtained from xenografts in mice, was minced with razor blades 
under sterile conditions. The fragments were then incubated for 16 hours at 40C in 
PBS containing trypsin (0.25 mg/ml) and dithioerythritol (3 mg/ml) as described 
by Bijman et al. (17). The suspensions obtained were subsequently heated to 374Ζ 
and agitated until complete disaggregation of the tissue had occurred. They were 
then passed through a sterile nylon filter (0 70 μτη) and collected in Eagle's 
Minimal Essential Medium (MEM), supplemented with 10% fetal bovine serum 
(FBS) (All tissue-culture materials were obtained from Gibco B.V., Breda, The 
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Table 6.1. Origin and histology of xenografts and their chemosensitixHty to cisplatin and bleomycin determined in тхю (nude mice) and 
in vitro (tumour slices) 
Tumour 
l.HN-2 
2.HN-2M 
3.HN-4 
4.HN-6 
5. HN-13 
6. HN-14 
7. HN-15 
Origin 
Epiglottic 
Lymph node metast. 
ofHN-2 
Pirif om sinus 
Tongue 
Flour of the mouth 
Epiglottis 
Trigonum retromol. 
Stage 
T2N1M0 
T2N1M0 
T2N1M0 
T1N0M0 
T2N0M0 
T1N1M0 
T2N1M0 
Histology 
Mod. diff. keratinizing 
squamous cell carcinoma 
Mod. diff. keratinizing 
squamous cell carcinoma 
Mod. diff. keratinizing 
squamous cell carcinoma 
Mod. to well diff. 
keratinizing squamous 
cell carcinoma 
Mod. to well diff. 
keratinizing squamous 
cell carcinoma 
Mod. to well diff. 
keratinizing squamous 
cell carcinoma 
Mod. to well diff. 
keratinizing squamous 
cell carcinoma 
cHEMOSENsmvmc 
in vivo in vitro 
Cispl. Bleom. Cispl. 
-
. 
+ + + 
+ 
+ + + 
+ 
+ + + 
Bleom. 
-
-
+ 
+ 
+ 
-
+ 
Netherlands). After washing the cells twice for 5 min. in fresh MEM + 10% FBS, 
the suspensions were diluted to a final concentration of 1.0 χ 10* cells/ml and 
divided over three incubation flasks, each containing 15 ml suspension. Cell 
viability, determined by trypan blue exclusion, varied between 65 and 80%. 
Cisplatin (Platinol; Bristol Myers, Madrid, Spain) was added to the first flask and 
bleomycin (Lundbeck, Copenhagen, Denmark) was added to the second. The final 
concentrations were 10 and 5 μg/ml, respectively. The third flask served as a 
control. 
The flasks were incubated at ЪТС in a humidified atmosphere with 5% COj in air. 
At regular intervals, 4 ml samples were taken from the flasks and divided over 
four test-tubes, 1 ml each, to which Ή-thymidine (S. A. 4 Ci/mmol; Radiochemical 
Centre, Amersham, England) was added. The final Ή-thymidme concentration 
was 1 цСі/тІ. After incubation for a further hour, ice-cold unlabeled thymidine 
was added to the test-tubes. The cells were then washed and collected on a filter 
(Schleicher & Schuil, no. 9) and subsequently dissolved in Luma Solve (Lumac 
Systems AG, Basel, Switzerland). The level of radioactivity incorporated in the 
samples was measured in a LKB 81000 Liquid Scintillation Counter. 
3.2.2. Tumour slices 
The tumour xenograft was extirpated under sterile conditions and transferred into 
cold MEM to a laminar flow cabinet for further preparation. Three adjacent slices 
of tumour tissue were obtained by using a device consisting of four razor blades 
mounted in a holder at a distance of 0.40 mm (19). For slicing, part of the tumour, 
trimmed to an appropriate size, was submerged in tissue culture medium in a 
Petri dish to avoid drying out. The blades were advanced through the tumour 
using a single gentle stroke. After loosening the bolts, the slices could easily be 
removed from the blades with a fine camel brush and deposited in the tissue 
culture medium. The slices were subsequently transferred to small flasks contai­
ning 2 ml incubation fluid. One slice was incubated in a test-tube containing 1.8 ml 
MEM plus 0.2 ml saline to serve as a control. The other two were placed in test-
tubes containing MEM to which either bleomycin or cisplatin dissolved in saline 
was added. The final concentrations were 10 μg cisplatin/ml and 5 μg bleo­
mycin/ml, respectively. For each assay three sets of three slices were incubated at 
ЗТС for varying periods of time. Incubation was performed under hyperbaric con­
ditions (1.8 atm. Oj), because hyperbaric oxygenation has been shown to enhance 
the uptake of Ή-thymidme in the deeper areas of tumour slices (20). During the 
last hour of incubation Ή- thymidine was added to the test-tubes to a final con­
centration of 1 цСі/т!. The slices were then washed in an isotonic solution of 
unlabelled thymidine for 3 hours at 4?C and subsequently dissolved in Luma Solve 
(Lumac Systems AG, Basel, Switzerland). Radioactivity was measured as 
described above. The cpm values of the Ή-thymidine incorporation measured in 
the control slices were set at 100%. The effects of the drugs were expressed as per­
centages of the control. 
3.2.3. Autoradiography 
To establish the specificity of Ή-thymidine incorporation, tumour slices were 
fixed in neutralized formaldehyde (4%) after incubation and processed for 
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embedding in paraffin wax. Sections (7 μπι) were coated with Ilford K5 emulsion 
and developed after an exposure time of 4 weeks. Staining was performed with 
haemotoxylin-eosin. 
3.3. Testing in mude mice 
For in vivo chemosensitivity testing, tumour-bearing nude mice were treated at a 
tumour size varying between 100 and 300 mm'. Bleomycin (dissolved in water) 
was administered subcutaneously at a dose of 25 mg/kg body weight at 48-hour 
time intervals, to a final dose of 100 mg/kg body weight. 
Cisplatin (dissolved in water) was given intraperitoneally at a dose of 3 mg/kg 
body weight at 48 hour-time intervals, to a final dose of 12 mg/kg body weight. 
The drug effects on the size of the tumours were measured with a Vernier caliper 
at two days intervals. Mice injected with water according to the same schedule, 
served as controls. 
4. Results 
4.1. Chemosensitivity testing in cell suspensions 
The incorporation of 3H-thymidine in single cell suspensions of 6 tumours is illu­
strated in Fig. 6.1. All suspensions show a steep decrease in Ti-thymidine incorpo­
ration during an incubation period of 4 hours in both control samples and samples 
to which cytotoxic agents were added. This observation makes it impossible to 
draw reliable conclusions regarding the effects of the drugs tested. 
4. 2. Chemosensitivity testing in tumour slices 
A typical example of the uptake of ^-thymidine in tumour slices throughout an 
incubation period of 86 hours is shown in Table 6.II. These data demonstrate that 
the isotope incorporation remained virtually unchanged for 30 hours. Thereafter a 
gradual decrease occurred resulting in about 50% of the initial value at 86 hours. 
Autoradiographs of the tumour slices revealed a specific incorporation of 'H-
thymidine in the nuclei of the tumour cells (Fig. 6.2). 
To determine the inter-slice variation of Ή-thymidine incorporation, sets of three 
slices of each tumour were used. The slices were incubated separately. The data 
obtained for tumour HN-13 demonstrated that there was good comparability 
between the different sets of slices (Table б.Ш). Comparable results were obtained 
for other xenografts and it was established that small tumours gave the best repro­
ducibility. This might be related to the amount of keratin and cell debris present. 
The results of the sensitivity tests on cisplatin and bleomycin in all the tumours 
tested are summarized in Fig. 6.3. Based on the interslice variation in 'H-thymidine 
incorporation, it was decided to conclude that there had been an inhibitory effect 
when the decrease in isotope incorporation was at least 30%. Initially, isotope 
incorporation was measured at 2, 5 and 24 hours, but because the inhibitory effect 
was most pronounced after 24 hours and no relevant information was obtained 
from the 2 measuring points during the first 5 hours, chemosensitivity testing was 
limited to one point at 4 hours in the later tests. 
The data presented in Fig. 6.3 show that both the primary tumour (HN-2) and the 
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time of incubation (h) 
Figure 6.1. Incorporation of'H-thymidine in single-cell suspensions from six squamous 
cell carcinoma xenografts (see Table 6. I) incubated for various periods with cisplatin 
(black bars) and bleomycin (dashed bars). There is a rapid decrease in ^-thymidine incor-
poration in both treated and control samples (open bars) with progression of time. 3H-
thymidine was added during the final hour of incubation. Each bar represents the mean ± 
SD of four samples. 
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Table б.ІІ. 3H-thymidine incorporation (cpm/slice) in tumour slices of tumour (HN-15) 
after various incubation periods. 'H-thymidine was added during the last hour of incuba­
tion. 
Time of incubation 
2 
6 
18 
30 
48 
60 
72 
86 
(b) cpm/ slice 
12342 
11,848 
11,725 
11,478 
10,738 
8,516 
7,899 
6,048 
(% of initial value) 
(100%) 
(96%) 
(95%) 
(93%) 
( 87%) 
(69%) 
(64%) 
(49%) 
Table 6.III. 'H-thymidine incorporation in 5 sets of tumour slices of tumour (HN-13) 
incubated for two hours. 'H-thymidine was added during the last hour of incubation. Each 
figure represents the mean (cpm/slice) of a set of three slices. 
Mean 
10,563 
9,952 
7,500 
7,223 
12,810 
S.D. 
995 
739 
278 
328 
1300 
S.D. as percentage of mean 
9.4 
7.4 
3.7 
4.5 
10.1 
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Figure 6.2. Micro-autoradiograph of a tumour slice incubated for 5 hours, in MEM + 
saline at 1.8 atm. O2. 3H-thymidine was added during the final hour of incubation. Note 
the labelling of tumour cell nuclei throughout the whole section (haematoxylin-eosin, 
x270). 
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Figure 6.3. Incorporation of Ή-thymidine in slices from seven different squamous cell 
carcinoma xenografts (see Table 6.1) incubated for various periods in the presence of 
cisplatin (A) and bleomycin (B). 3H-thymidine incorporation is expressed as a percentage 
of the control (100%). Each bar represents the mean ± SD of3 slices. 3H-thymidine was 
added during the final hour of incubation. 
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incubat ion 
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^ 5 fu 
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Figure 6.4. Incorporation of 'H-thymidine in slices from a squamous cell carcinoma, 
directly obtained from a patient, incubated for 24 hours with cisplatin, 5-FU and a combi­
nation of cisplatin and 5-FU. 'H-thymidine incorporation is expressed as a percentage of 
the control (open bar 100%). Each bar represents the mean ± SD of3 slices. 'H-thymidine 
was added during the final hour of incubation. 
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lymph node metastasis (HN-2M) were not sensitive to either bleomycin or 
cisplatin after an incubation period of up to 24 hours. Tumours HN-4, HN-13 and 
HN-15 revealed marked inhibition of 3H-thymidine incorporation for both drugs. 
The sensitivity of tumour HN-6 was limited to bleomycin; no effect could be esta­
blished for cisplatin. Tumour HN-14 revealed an exclusive sensitivity to cisplatin. 
Comparison of these data with the effects of cisplatin and bleomycin on the same 
tumours in nude mice, demonstrated the existence of a close correlation between 
the results of the in vivo and in vitro chemosensitivity tests (Table 6.1). Only the in 
vitro sensitivity of tumour HN-14 to cisplatin could not be reproduced in nude 
mice. 
The testing of these tumour lines during different passages failed to show any 
change in their chemosensitivity features. 
So far, the applicability of this in vitro technique to the clinical setting could only 
be tested on one patient, who had a squamous cell carcinoma of the tongue. Slices 
of a biopsy of this tumour were incubated either with cisplatin (final concentra­
tion 10 mg/ml), 5-FU (5-fluororacil, Abie Ltd., Ramat-Gan, Israel) (final concentra­
tion 200 μg/ml) or a combination of both drugs. 
Especially 5-FU and the combination of both drugs showed a marked decrease in 
the incorporation of 3H-thymidine after 24 hours of incubation (Fig. 6.4). The 
patient was treated with a combination of both drugs and complete regression of 
the tumour was established after 4 months. 
5. Discussion 
The use of human tumour xenografts grown in nude mice as a model for testing 
anti-tumour drugs has several advantages. Apart from the availability of sufficient 
tumour material for multiple experiments, this approach offers the opportunity to 
compare the validity of in vitro assays with in vivo testing in nude mice. 
From the results obtained in the present study it is obvious that the use of single-
cell suspensions is not a reliable technique for chemosensitivity testing, at least for 
squamous cell carcinomas of the head and neck region. This is especially due to 
the rapid decrease of 3H-thymidine incorporation during incubation, which 
reflects a severe loss of cell viability. These findings deviate from comparable 
studies on several other types of solid tumours, in which single cell suspensions, 
prepared with similar disaggregation procedures, were employed to study the 
dose-response relationship of cytotoxic drugs (21, 22). Unfortunately, these studies 
give no clear impression of the behaviour of these suspensions during incubation, 
because no absolute figures are given on the uptake of 3H-thymidine. 
The discrepancy between cell suspensions of squamous cell carcinoma and other 
types of solid tumour is most likely due to the peculiar histological architecture of 
squamous cell carcinomas. Especially the multiple intercellular junctions may be 
assumed to make the cells more susceptible to irreversible damage by the disag­
gregation procedures used, which will lead to massive cell death during incuba­
tion. This suggestion is supported by the observation that slices of the same 
tumour, incubated in the same medium, did not show this loss of vitality. Also the 
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low plating and low cloning efficiency of these tumours in the clonogenic assay 
(15,16), seem to be in line with this suggestion. 
In contrast to the experience with cell suspensions for cytotoxic drug testing, the 
results obtained using thin slices are very encouraging. With this method the 
viability of the cells, based on Ή-thymidme incorporation, could be maintained at 
a high stable level during an incubation period of up to 30 hours. 
The fact that in 6 out of 7 cases close similarity was found between the effects of 
bleomycin and cisplatin on tissue slices and the same tumours in nude mice 
supports the validity of this method. The reason for the discrepancy between the 
cisplatin sensitivity in vivo and in vitro in one of the tumours tested remains 
obscure. 
Although the results of chemosensitivity testing obtained with xenografts cannot 
simply be transferred to the condition in the patient, a close correlation has been 
established between the tumour response in the patient and this approach (3, 4, 
23). 
In summary, this in vitro study demonstrates that the use of slices for the chemo­
sensitivity testing of squamous cell carcinomas, is far superior to the use of single-
cell suspensions. It avoids the selection of cells and prevents cellular damage 
which may lead to serious metabolic disturbances or cell death. 
The observations made on slices of xenografts, together with the very accurate pre­
diction of the tumour response with slices of a tumour biopt, strongly suggests 
that this is a promising technique for chemosensitivity testing. Whether this 
procedure is suitable for tumour material directly obtained from patients needs 
further verification on a larger scale. 
115 
6. References 
1. Hoff von DD and Weisenthal L. In vitro methods to predict the patient's 
response to chemotherapy. Adv Pharmacol Chemother 17:133-156,1980. 
2. Mattem J, Wayss К and Volm M. Sensitivity of human non-small cell lung 
cancer xenografts to cyclophosphamide and cisplatin. In Vivo 1: 23-26, 
1987. 
3. Winograd B, Boven E, Lobbezoo MW and Pinedo HM. Human tumor 
xenografts in the nude mouse and their value as test models in anticancer 
drug development (review). In Vivo 1:1-14,1987. 
4. Giovanella ВС, Stehlin JS, Shephard RC and Williams JL. Correlation 
between response to chemotherapy of human tumors in patients and in 
nude mice. Cancer 52:1146-1152,1983. 
5. Bogden AE, Kelton DE, Cobb WB and Esber HJ. A rapid screening method 
for testing chemotherapeutic agents against human tumor xenografts. In: 
Proc symp on the use of athymic mice in cancer research. Houchens DD 
and Ovejera AA (Eds). Fischer Verlag, New York, pp 231-250,1978. 
6. Bogden AE, Cobb WB, Lepage DJ, Haskell PM, Guikin ТА, Ward A, 
Kelton DE and Esber HJ. Chemotherapy responsiveness of human tumors 
at first transplant generation xenografts in the normal mouse. Cancer 48: 
10-20,1981. 
7. Rajnay J, Kopper L and Kapis K. Chemotherapeutic response of squamous 
cell carcinoma xenografts (subcutaneous and subrenal capsule assay). 
Oncology 44: 307-311,1987. 
8. Levi FA, Blum JP, Lemaigre G, Bourut C, Reinberg A and Mathé G. A 
four-day subrenal capsule assay for testing the effectiveness of anticancer 
drugs against human tumors. Cancer Res 44: 2660-2667,1984. 
9. Volm M, Wayss K, Kaufmann M and Mattem J. Pretherapeutic detection 
of tumour resistance and the results of tumour chemotherapy. Eur J 
Cancer 15: 983-993,1979. 
10. Hamburger AW and Salmon SE. Primary bioassay of human tumor stem 
cells. Science 197: 983-993,1977. 
11. Hoff von DD, Cowan J and Harris G.: Human tumor cloning feasibility 
and clinical correlations. Cancer Chemother Pharmacol 6: 265-271,1981. 
12. Salmon SE. Development and applications of a human tumor colony assay 
for chemosensitivity testing. Ree Res Cancer Res 94:8-16,1984. 
13. Selby P, Buick RN and Tannock J. A critical appraisal of the human tumor 
stem-cell assay. N Engl J Med 308:129-134,1983. 
14. Hill BT. Screening of new drugs and analogues specificity and selectivity. 
Cancer Treat Rev 14:197-202,1987. 
15. Johns ME and Mills SE. Cloning efficiency. A possible prognostic indica-
tion in squamous cell carcinoma of the head and neck. Cancer 52: 1401-
1404,1983. 
16. Mattox DE, Hoff von DD, Clark GM and Aufdemorte TB. Factors that 
influence growth of head and neck squamous carcinoma in the soft agar 
cloning assay. Cancer 53:1736-1740,1984. 
116 
17. Bijman JTh, Wagener DJTh, Rennes van H, Wessels JMC and van den 
Broek P. Flow cytometric evaluation of cell dispersion from human head 
and neck tumors. Cytometry 6:334-341,1985. 
18. Elprana D, Kuijpers W, van den Broek Ρ and Wagener DJTh. Growth char­
acteristics of head and neck squamous cell carcinoma in nude mice. Eur J 
Cancer Clin Oncol 22:1211-1222,1986. 
19. Elprana D, Schwachöfer J and Kuijpers W. A device for the production of 
fresh tumour slices for cytotoxic drug testing. Tumor Biol 10:324-329,1989. 
20. Meyer JS and Conner RE. In vitro labelling of solid tissues with tritiated 
thymidine for autoradiographic detection of S-phase nuclei. St Technol 52: 
185-195,1977. 
21. Sanfilippo O, Daidone MG, Zaffaroni N and Silvestrini R. Development of 
a nucleotide precursor incorporation assay for testing drug sensitivity of 
human tumors. Ree Res Cane Res 94:127-139,1984. 
22. Shrivastav S, Bonar RA, Stone KR and Paulson DF. An in vitro assay 
procedure to test chemotherapeutic drugs on cells from human solid 
tumors. Cancer Res 40:4438-4442,1980. 
23. Fiebig HH, Schuchhard C, Hens H, Fiedler L and Löhr GW. Comparison 
of tumor response in nude mice and in patients. Behring Inst Mitt 74: 343-
352,1984. 
117 

SUMMARY AND CONCLUSIONS 
SUMMARY AND CONCLUSIONS 
Over the years both in vivo and in vitro models have been developed to study the 
biological behaviour of malignant tumours outside the human body. From all 
these models, the thymus-aplastic nude mouse, which was introduced in the late 
sixties, has received increasing interest as an in vivo model to study the behaviour 
of various human malignancies. In the nude mouse, xenografts of many human 
tumours has been successfully cultured for many generations, generally without 
significant changes in the original tumour characteristics. 
In this thesis, the nude mouse was used as a culture model for human squamous 
cell carcinomas of the head and neck region. 
In chapter I a general review is given of the various in vivo an in vitro models 
which have been introduced for studying tumour behaviour and cytotoxic drug 
testing. 
Chapter Π deals with the transplantability and growth characteristics of head and 
neck squamous cell carcinomas in nude mice. A high take rate was achieved, 
while no distinct relationship could be established between the take rate and histo­
logical differentation. This score was much higher than the take rate obtained in 
comparable studies. 
The xenografts appeared to retain their original microscopical appearance and 
degree of histological differentiation. No metastases were found, yet incidentally 
tumour invasion was observed into the surrounding fibrous capsule. 
On the basis of comparisons of growth curves and histological observations, it was 
concluded that growth curves alone are not a reliable evaluation parameter for 
tumour growth and the amount of vital tumour tissue present, because of the 
rapidly increasing accumulation of cellular debris and keratin lamellae within the 
tumour. As the contribution of non-vital material to the tumour volume only 
became significant at a tumour diameter of more than 4 mm, the time needed for 
the tumour to reach a general mean diameter of about 4 mm (initial lag-phase) was 
chosen as a more reliable parameter for tumour growth. 
It is concluded that head and neck carcinomas do not belong to the category of 
tumours which are difficult to grow in nude mice. The discrepancies between the 
take rates in the present and other studies are suggested to be due to technical and 
methodological differences in the grafting procedures. 
Besides the maintenance of the original histological features, the preservation of 
the DNA profile of the donor tumour is of crucial importance to prove that the 
original clonal composition of the primary tumour has been preserved in the 
xenograft lines. This is especially important because of the relationship suggested 
in several studies between DNA ploidy and responsiveness to therapy and the 
prognosis. Most of the studies have shown that the original DNA profUe does not 
change after xenografting, but some xenografted renal cell carcinomas and osteo­
sarcomas have shown instability of the DNA profUe after long-term transplanta­
tion in the nude mouse. 
The question of the stability of the DNA profile of squamous cell carcinoma of the 
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head and neck region after xenografting has been addressed in chapter ΠΙ, with 
the use of DNA cytometry. 
DNA flow cytometry showed an apparent bimodal DNA distribution with an 
euploid and an aneuploid peak in both the primary tumours and their xenografts. 
During passaging, the relative proportions of both cell populations could vary, but 
the DNA indices remained stable. The euploid cell population in tumours with a 
bimodal DNA distribution is usually assumed to be of host origin, but conclusive 
evidence is lacking. As routine DNA flow cytometry does not discriminate 
between mouse host cells and euploid human cells, DNA image cytometry was 
applied. This technique allows to distinguish between normal host cells and 
euploid tumour cells. It was clearly shown that the euploid peak represented 
normal host cells in all the tumours studied. In addition, the mouse orgin of the 
xenograft stroma was confirmed immunohistochemically with an antibody specifi­
cally directed against mouse endothelium. 
The preservation of the features of the primary tumour, including the DNA distri­
bution after xenografting, confirms the value of this model for testing cytotoxic 
drugs. Good correlations have been found in various comparative studies on che­
motherapy in patients and xenografts. The evaluation of treatment effects on xeno­
grafts has relied largely on changes in the tumour volume, but this method has not 
yet been standardized. Therefore it was tried to gain more insight into this method 
by also employing other parameters. 
Chapter IV describes chemosensitivity testing of xenografts of squamous cell carci­
nomas of the head and neck region for cisplatin and bleomycin. These drugs have 
proved to be effective in patients with head and neck cancer. In addition to 
changes in the tumour volume, also histology, DNA-flow cytometry and the inci­
dental use of Ή-thymidine were incorporated as parameters for evaluating drug 
sensitivity. 
Three tumours were found to be highly sensitive to both drugs, while only one 
showed sensitivity to bleomycin. The remaining 4 tumours failed to show any 
responsiveness during drug treatment. 
Comparison of the growth curves and histological sections revealed that the 
tumour volume alone (growth curves) was not a reliable parameter for measuring 
the effect of the drug in strongly keratinizing tumours, because of the substantial 
contribution of the accumulated keratin, which persisted after disappearance of 
the tumour cells, to the tumour volume. 
It is concluded that additional parameters are required for a reliable evaluation of 
drug sensitivity. 
In view of the rapid changes of the DNA profile after drug exposure DNA flow 
cytometry is suggested as an excellent approach to monitor chemosensitivity. 
Regrowth occurred in all the sensitive tumours even after repeated treatment. The 
recurrent tumour did not show any change in histological features, DNA index or 
chemosensitivity. 
Approaches for predicting drug sensitivity include either xenografts in immunolo­
gically incompetent laboratory animals or in vitro tests. The in vivo models can be 
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assumed to be superior to the in vitro models, where cells are cultured in an artifi­
cial environment and the pharmacokinetic influences of the drugs are absent. 
However, the main disadvantage of in vivo models is that a direct comparison 
between a xenograft and the primary tumour is difficult, because of the long time 
needed to establish a tumour line and subsequently chemosensitivity testing. For 
practical reasons in vitro tests are preferred. Several in vitro predictive tests have 
been developed for the rapid screening of cytotoxic drug sensitivity, but at present 
none of these tests have produced satisfactory results. 
In Chapter V a new device is introduced allowing the production of sets of slices 
of equal thickness from tumour xenografts. Incubation of these slices under hyper­
baric 0 2 showed a reproducible stable incorporation of 'H-thymidine for periods 
of more than 24 hours. Preliminary data on the effect of cytotoxic drugs showed a 
close correlation between the in vitro effect and the in vivo sensitivity in nude 
mice. 
Chapter VI deals with two different in vitro techniques for chemosensitivity 
testing of xenografted head and neck squamous cell carcinomas, using 'H-
thymidine as a parameter. Besides the use of thin tumour slices, single cell suspen­
sions were used. 
It appeared that in all the cell suspensions of drug-exposed samples and controls, 
the incorporation of Ή-thjrmidine showed a fairly sharp decrease during the first 
few hours of incubation. So no reliable conclusions could be drawn regarding the 
drug effects. 
In vitro incubation of tumour slices in the same culture medium showed the stable 
incorporation of 3H-thymidine for 30 hours in all the control specimens. 
Autoradiography revealed 3H-thymidine incorporation into the nuclei of the 
tumour cells throughout the whole slice. Slices obtained from tumours which were 
found to be sensitive to cisplatin or bleomycin in vivo in the nude mouse, showed 
pronounced inhibition of the incorporation of 3H-thymidine when exposed to 
these drugs. In one tumour, which was found to be insensitive in the nude mouse, 
in vitro sensitivity for cisplatin was observed. 
In addition to these slices of xenografts, slices of one primary tumour were tested. 
Chemosensitivity testing of slices from this tumour showed close correlation with 
the patient's response to the same drugs. 
The results obtained with the tumour slices seem to be very promising and show 
that chemosensitivity testing of tumour slices appears to be far superior to the use 
of single cell suspensions, at least for squamous cell carcinomas. 
It is suggested that the disaggregation procedures for obtaining cell suspensions 
result in irreversible damage to the epithelial cells, leading to cell death. This may 
be especially marked in epithelial tumours, where the multiple intercellular 
junctions make the cells more susceptible to damage by the disaggregation proce­
dures. This phenomenon is most probably the main underlying cause of the low 
plating efficiency encountered in in vitro culturing of these tumour cells. 
In summary, the observations made in the present study demonstrate the value of 
the nude mouse as a reliable in vivo model for studying the biology and chemo­
sensitivity of head and neck squamous cell carcinomas. Although the clinical value 
of the nude mouse model for the individual patient remains doubtful, the intro-
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duction of the tumour slice technique may offer better perspectives for testing 
drug sensitivity in the individual patient. 
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SAMENVATTING EN CONCLUSIES 
Voor de bestudering van het gedrag van maligne tumoren buiten het menselijk 
lichaam zijn zowel in vivo als in vitro modellen ontwikkeld. 
Aan het eind van de jaren zestig werd hiervoor de thymusloze, naakte muis geïn-
troduceerd. Vanaf die tijd is dit in vivo model in toenemende mate in het middel-
punt van de belangstelling komen te staan voor het bestuderen van het gedrag van 
maligne tumoren. Een grote variatie aan maligne humane tumoren is in dit 
proefdier gedurende vele opeenvolgende generaties gekweekt, zonder dat er sig-
nificante veranderingen optraden in de oorspronkelijke eigenschappen van de 
tumoren. 
In dit proefschrift wordt een onderzoek beschreven, waarin de naakte muis is 
gebruikt als model voor het kweken van humane plaveiselcelcarcinomen uit het 
hoofd-halsgebied. 
In het eerste hoofdstuk wordt een overzicht gegeven van de verschillende in vivo 
en in vitro modellen die in de loop der jaren geïntroduceerd zijn voor het bestu-
deren van het gedrag van maligne tumoren en het testen van hun gevoeligheid 
voor cytostatica. 
In hoofdstuk II worden de resultaten beschreven van een onderzoek naar de trans-
planteerbaarheid en de groei van plaveiselcelcarcinomen uit het hoofd- halsgebied 
in de naakte muis. In dit onderzoek werd een hoge take rate bereikt, die veel hoger 
was dan in vergelijkbare studies en geen relatie vertoonde met de differentiatie-
graad van de tumoren. De xenotransplantaten behielden de histologische ken-
merken van de oorspronkelijke tumoren. Er werden geen metastasen waarge-
nomen, maar in enkele tumoren werd infiltratie van de tumor in het omringende 
kapsel gevonden. 
Histologisch onderzoek toonde aan dat groeicurves, op basis van het volume van 
de tumoren, geen betrouwbare weergave vormen voor de groei van de tumoren 
en de hoeveelheid vitaal tumorweefsel, vanwege de snelle toename van de hoe-
veelheid kératine en necrotisch materiaal bij tumoren met een diameter groter dan 
ongeveer 4 mm. Om die reden werd de tijd die nodig was voor de tumoren om 
een dergelijke diameter te bereiken (initial lag-phase) gekozen als een meer 
betrouwbare parameter voor de groeisnelheid van deze tumoren. 
Uit dit onderzoek werd de conclusie getrokken dat hoofd-halstumoren niet 
behoren tot de categorie tumoren die moeilijk in de naakte muis getransplanteerd 
kan worden. De verschillen in take rate met vergelijkbare studies worden toege-
schreven aan methodische verschillen en verschillen in transplantatietechniek. 
Naast het behoud van de oorspronkelijke histologische kenmerken, is het van 
essentieel belang te weten of het DNA-profiel van de oorspronkelijke tumor, na 
xenotransplantatie, ongewijzigd blijft. Hiermee wordt bewezen dat de oorspronke-
lijke clonale samenstelling van de tumoren in de xenotransplantaten bewaard 
blijft. Dit is met name van belang, vanwege de relatie die er volgens verschillende 
onderzoekingen bestaat tussen DNA-pIoidy en prognose en de reactie op ver-
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schillende therapieën. In het merendeel van de betreffende studies is aangetoond 
dat het oorspronkelijke DNA profiel van tumoren niet verandert na xenotrans-
plantatie in de naakte muis, alleen bij niercarcinomen en osteosarcomen is inciden-
teel een instabiliteit in het DNA profiel waargenomen na langdurige passage in de 
naakte muis. 
De stabiliteit van het DNA profiel van plaveiselcelcarcinomen uit het hoofd- hals-
gebied na xenotransplantatie werd onderzocht m.b.v. DNA flow cytometrie en is 
beschreven in hoofdstuk ΙΠ. 
De onderzochte primaire tumoren en hun xenotransplantaten vertoonden met 
DNA flow cytometrie een bimodale DNA verdeling, met een euploide en een 
aneuploide piek in het DNA histogram. Tijdens de verschillende passages in de 
naakte muis traden er variaties op in de verhouding van deze twee celpopulaties, 
maar de DNA indices bleven ongewijzigd. Van de euploide celpopulatie in de 
xenotransplantaten wordt algemeen aangenomen dat dit normale gastheercellen 
zijn, maar een experimentele onderbouwing ontbreekt. Met de gebruikte routine 
DNA flow cytometrie kon geen duidelijk onderscheid gemaakt worden tussen 
normale muizecellen en euploide humane cellen. Daarom werd gebruik gemaakt 
van DNA image cytometrie, waarmee deze celpopulaties wel van elkaar kunnen 
worden onderscheiden. Met deze techniek werd aangetoond, dat de euploide piek 
in alle onderzochte tumoren uit normale gastheercellen bestond. Daarnaast werd 
met behulp van een antilichaam, specifiek gericht tegen endotheelcellen van de 
muis, aangetoond dat het stroma van de xenotransplantaten van de muis af­
komstig was. 
Het behoud van de kenmerken van de primaire tumor, inclusief het DNA profiel, 
bevestigt de waarde van dit model voor het testen van cytostatica. In vergelijkende 
onderzoekingen naar de effecten van cytostatica op verschillende tumoren zijn 
goede correlaties gevonden tussen de effecten op de primaire tumor en de xeno­
transplantaten in de naakte muis. 
Het meten van de effecten van verschillende therapieën op xenotransplantaten 
berust grotendeels op veranderingen van het volume van de tumor, maar hiervoor 
bestaat geen gestandaardiseerde methode. In dit onderzoek werd getracht meer 
inzicht te verkrijgen in de waarde van deze methode en deze te vergelijken met 
andere parameters. 
Het testen van de gevoeligheid van xenotransplantaten van plaveiselcel- carci-
nomen uit het hoofd-halsgebied voor cisplatinum en bleomycine wordt in 
hoofdstuk IV beschreven. Van deze twee cytostatica is bekend dat ze effectief zijn 
bij de behandeling van deze tumoren. Naast het volume van de tumoren, werden 
het histologisch beeld, DNA flow cytometrie en bij enkele tumoren de incorporatie 
van 'H-thymidine als parameters gebruikt voor het meten van de gevoeligheid 
van de xenotransplantaten voor deze cytostatica. Bij 3 tumoren werd een sterke 
gevoeligheid gemeten voor zowel cisplatinum als bleomycine, terwijl één tumor 
gevoelig was voor één van deze stoffen. Bij de resterende 4 tumoren werd geen 
effect waargenomen. Er kon geen verband worden vastgesteld tussen de differen-
tiatiegraad en de gevoeligheid voor deze cytostatica. 
Uit een vergelijking van de groeicurves met het histologisch beeld kwam naar 
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voren dat de groeicurves in die gevallen, waar de tumoren veel kératine produ-
ceerden geen juiste weergave vormden van de mate waarin het cytostaticum 
effectief was. Dit was het gevolg van het persisteren van kératine na het ver-
dwijnen van de tumorcellen. Op grond van deze waarnemingen werd de conclusie 
getrokken dat, naast het volume van de tumor, andere parameters nodig kunnen 
zijn om vast te stellen in welke mate tumoren gevoelig zijn voor behandeling met 
cytostatica. Op grond van de snelle veranderingen, die na toediening van cytosta-
tica, m.b.v. DNA flow cytometric in het DNA-profiel van gevoelige tumoren 
worden waargenomen, wordt deze techniek voorgesteld voor een snelle screening 
van de effectiviteit van chemotherapie. 
Alle xenotransplantaten, die gevoelig waren voor cytostatica, vertoonden hergroei 
na beëindiging van de therapie. In deze "recidieftumoren" waren na drie achter-
eenvolgende behandelingen geen veranderingen waarneembaar met betrekking 
tot de histologische kenmerken, DNA index en gevoeligheid voor cytostatica. 
Om de gevoeligheid van tumoren voor cytostatica te testen, worden zowel in vitro 
cultures als xenotransplantaten in immunologische incompetente proefdieren 
gebruikt. De in vivo modellen lijken hiervoor meer geschikt dan de in vitro 
modellen, waar de cellen in een artificieel medium worden gekweekt, waar de 
pharmacokinetische invloed van de cytostatica afwezig is. Een belangrijk nadeel 
van de in vivo modellen is echter, dat een directe vergelijking van de donorpatiënt 
met het xenotransplantaat erg moeilijk is vanwege de lange periode die er nodig is 
om voldoende groei van de tumoren te krijgen en deze op hun gevoeligheid voor 
cytostatica te testen. Om practische redenen wordt daarom de voorkeur gegeven 
aan in vitro tests. Voor een snelle bepaling van de gevoeligheid van tumoren voor 
cytostatica zijn er verschillende in vitro tests ontwikkeld maar tot op heden heeft 
echter geen van deze tests bevredigende resultaten opgeleverd. 
In hoofdstuk V wordt een nieuwe in vitro methode geïntroduceerd, waarmee sets 
van aan elkaar grenzende tumorcoupes, die een gelijke dikte hebben, kunnen 
worden gemaakt. Incubatie van deze coupes onder hyperbare zuurstof, liet een 
reproduceerbare stabiele incorporatie van 3H-thymidine zien gedurende een 
periode van meer dan 24 uur. Een pilotstudie met deze methode naar het effect 
van cytostatica toonde een nauwe correlatie aan tussen de in vitro effecten en de 
in vivo gevoeligheid in de naakte muis. 
In hoofdstuk VI wordt de vergelijking van twee verschillende in vitro technieken, 
dunne coupes en celsuspensies, voor het meten van de gevoeligheid van xeno-
transplantaten van plaveiselcelcarcinomen uit het hoofd-halsgebied voor cytosta-
tica beschreven. Hierbij werd de incorporatie van 'H-thymidine als parameter 
gebruikt. 
Incubatie van celsuspensies van deze tumoren, toonde zowel bij de controle 
coupes als na toevoeging van cytostatica een sterke afname van de incorporatie 
van 'H-thymidine aan tijdens de eerste uren van de incubatieperiode. Hierdoor 
konden geen betrouwbare conclusies getrokken worden over de gevoeligheid van 
de tumoren voor de toegevoegde cytostatica. Incubatie van tumorcoupes in 
hetzelfde medium liet daarentegen in alle controle coupes een stabiele incorporatie 
van 'H-thymidine zien gedurende een periode van meer dan 30 uur. M.b.v. auto-
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radiografíe kon aangetoond worden dat door de hele dikte van de coupe incorpo-
ratie van T-I-thymidine in de tumorcellen was opgetreden. Coupes van tumoren 
die in de naakte muis gevoelig waren voor cisplatinum en/of bleomycine, ver-
toonden een sterke remming van de Ή-thymidine opname na toevoeging van 
deze stoffen aan het incubatiemedium. Deze remming trad niet op bij de ongevoe­
lige tumoren. Bij één tumor echter, waar de opname van Ή-thyimdine in vitro 
duidelijk geremd werd door cisplatinum, kon in de naakte muis geen effect 
worden vastgesteld. 
Naast coupes van xenotransplantaten werden de coupes van 1 primaire tumor 
met deze methode onderzocht. De in vitro gemeten gevoeligheid voor drie cyto-
statica correspondeerde met de totale remissie van de tumor, na behandeling van 
de patient met dezelfde cytostatica. 
De resultaten die verkregen zijn met de coupemethode lijken veelbelovend en 
tonen aan dat in ieder geval voor plaveiselcelcarcinomen het gebruik van coupes 
als model voor het testen van de gevoeligheid van cytostatica aanzienlijk beter is 
dan het gebruik van celsuspensies. 
De slechte resultaten die met celsuspensies werden verkregen worden geweten 
aan de disaggregatieprocedures, waardoor de cellen een irreversibele beschadi­
ging kunnen ondergaan en vervolgens snel afsterven. De beschadiging zal speciaal 
tot uiting komen bij epitheliale tumoren, omdat deze gevoeliger zijn voor disag-
gregatie, als gevolg van de multipele verbindingen tussen de cellen onderling. Dit 
is mogelijk ook de oorzaak van de lage "plating efficiency" bij het kweken van 
deze cellen in vitro. 
Samengevat tonen de hier beschreven resultaten aan dat xenotransplantaten van 
plaveiselcelcarcinomen uit het hoofd- habgebied in de naakte muis een betrouw­
baar model vormen voor de bestudering van het biologisch gedrag en de gevoelig­
heid voor cytostatica. De klinische waarde van de naakte muis als model voor de 
behandeling van de individuele patient is echter twijfelachtig. De introductie van 
de tumor slice techniek lijkt voor het testen van de gevoeligheid van cytostatica 
betere perspectieven te bieden voor de individuele patiënt. 
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